

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol of A Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014475
Article Type:	Protocol
Date Submitted by the Author:	27-Sep-2016
Complete List of Authors:	Deng, Jingwen; Dermatology Yao, Danni; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Lu, Chuan-jian ; Guangdong Provincial Hospital of Traditional Chinese Medicine, Department of dermatology Wen, Zehuai; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Deng, Hao; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Yan, YuHong; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology He, Ziyang; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Wu, Huimei; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, Chinese medicine, Clinical Trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol of A Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Jingwen Deng^{1,2,†}, Danni Yao^{1,2,†}, Chuanjian Lu^{1,2,3*}, Zehuai Wen⁴,
Hao Deng^{1,2}, Yuhong Yan^{1,2}, Ziyang He¹, Huimei Wu^{1,2}

Abstract

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Introduction: Psoriasis vulgaris (PV) is a common skin disease characterized by persistent localized erythematous scaly plaques. Yinxieling is a Chinese herbal formula for psoriasis, which has been used for more than 20 years in China. For facilitating application, PSORI-CM01 is developed from the optimization and simplification of Yinxieling tablet determined in the previous study and clinical practice. However, the scientific evidence for whether the PSORI-CM01 is more effective compared with original Yinxieling for psoriasis is still insufficient. Therefore, we designed a randomized clinical trial to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granule compared with Yinxieling tablet on patients with psoriasis.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Methods and analysis: This on-going study is a two-arm parallel, randomized, double-blind, double-dummy clinical trial. 556 participants with psoriasis will be recruited and then randomly allocated into two groups in a 1:1 ratio. Participants in PSORI-CM01 group will receive PSORI-CM01 granule 5.5 g twice daily and five placebo tablets three times daily for 12 weeks. Participants in Yinxieling group will receive five Yinxieling tablets three times daily and placebo granule twice daily for 12 weeks. The primary outcome is reduction of Psoriasis Area and Severity Index (PASI) score. The secondary outcomes include relapse rate, visual analogue scale (VAS), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI). Cost effectiveness analysis will be carried out from a health and community care provider perspective.

46
47
48
49
50
51
52
53
54

Ethics and dissemination: This research protocol had been reviewed and approved by the institutional review boards of three trial centres (Guangdong Provincial Hospital of Chinese Medicine (B2014-026-01), Affiliated Hospital of Tianjin Chinese Medicine Academy (2014-KY-001) and Third Hospital of Hangzhou (B2014-026-01)). The findings will be disseminated to the public through conference presentations and open access journals.

55
56
57

Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-14005185

58
59
60

[†]Jingwen Deng and Danni Yao contributed equally to this work.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*** Correspondence:**

Chuanjian Lu

luchuanjian888@vip.sina.com

Strengths and limitations of this study

- We are carrying out a distinctive trial to provide evidence about the clinical effectiveness of Chinese medicine treatment for psoriasis before and after optimization and simplification.
- Participants will be randomised to either PSORI-CM01 granules with Yinxieling placebo tablet group or Yinxieling tablet with PSORI-CM01 placebo granules group.
- Primary outcome is reduction of PASI score during the treatment period and follow-up period.
- This trial is powered to show the effect of Chinese medicine on relieving symptoms of psoriasis

Authors' information

1. Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China;
2. Psoriasis clinical and basic research team, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou 510120, China;
3. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 510120, China
4. Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Authors' contact information

JingWen Deng, e-mail: s6891@163.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

DanNi Yao, e-mail: yaodanni1984@163.com,

Tel:+8620-81887233-30603, Fax:+8620-81874903

ChuanJian Lu, e-mail: luchuanjian888@vip.sina.com

Tel:+8620-81887233-31223, Fax:+8620-81874903

ZeHuai Wen, e-mail: wenzh@gzucm.edu.cn,

Tel:+8620-81887233-31227, Fax:+8620-81874903

Hao Deng, e-mail: 563435624@qq.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tel:+8620-81887233-35934, Fax:+8620-81874903

YuHong Yan, e-mail: yanyuhong7966@139.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

ZiYang He, e-mail: ziyanghe@qq.com,

Tel:+8620-81887233-31227, Fax:+8620-81874903

HuiMei Wu, e-mail: 691892927@qq.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

For peer review only

Background:

Psoriasis is a chronic, immune-mediated, inflammatory disease skin disease characterized by erythema, scale and redness, thickening and scaling of the skin. Its main histopathologic change is accelerated cell proliferation of keratinocytes^{1, 2}. However, its cause is still unknown. Though early concept of the pathogenesis of psoriasis focuses on the proliferation and differentiation of the keratinocytes, recent studies have recognized that dysregulation of immune system plays a critical role on the development of psoriasis. The interactions between dendritic cells, T cells, keratinocytes, neutrophils, and the cytokines released from immune cells are the core mechanism of how psoriasis developed³. Genetic, environmental and behavioral factors are thought to be triggers contribute to the onset of psoriasis⁴. The prevalence of psoriasis is estimated that the prevalence of the disease in adults ranges from 0.91% to 8.5% worldwide⁵. Clinically, psoriasis vulgaris is the most common subtype of psoriasis affecting approximately 90% of patients⁶. Psoriasis can also cost huge amount of economic loss. According to a systematic literature review conducted by the American academy of dermatology, the total burden of psoriasis was estimated as \$35.2 billion in the U.S. per annum, directly and indirectly⁷.

The most common treatments for psoriasis include topical medication, ultraviolet light, systematic drugs and biologics. Topical medications such as corticosteroids, retinoid and vitamin D analogues, are considered to be first line therapies for psoriasis vulgaris. Systematic drugs are for sever psoriasis, while ultraviolet lights and biologics are used when applicable and necessary⁸.

A series of systematic reviews have shown that Chinese Medicine is an effective therapy for psoriasis⁹⁻¹⁷. Yinxieling tablet, a Chinese herbal medicine compound preparation with 10 ingredients (*angelica sinensis*, *radix paeoniae rubra*, *chloranthus spicatus*, *smoked plum*, *radix rehmanniae recen*, *ligusticum wallichii*, *radices lithospermi*, *curcuma zedoary*, *rhizome smilacis glabrae*, *liquorice*) for psoriasis, was developed by National Medical Master Guo-wei Xuan, a well-known Chinese medicine doctor. It was formulated according to traditional Chinese medicine theory, and was theoretically effective and safe. In resent 20 years clinical practice, Yinxieling tablets have been extensively used for treating psoriasis and shown a promising clinical efficacy on relieving symptoms of psoriasis and reducing relapsing rate. Molecular biological technologies were used to analyze the pharmacological mechanisms of multiple ingredients in Yinxieling tablet^{18, 19}. These researches showed that Yinxieling tablets involved in the regulation of immune-mediated cells and interaction of cellular cytokines, which revealed the potential mechanism of Yinxieling tablets on psoriasis. When molecular and pharmacological mechanisms were explored, two clinical trials were carried out for confirming its clinical effectiveness. In Wang's study, 24 patients with psoriasis were equally randomized into two groups: treatment group received Yinxieling tablet for eight weeks and the

1
2
3 control group received Acitretin capsule for eight weeks. The therapeutic effect of
4 Yinxieling tablet for the treatment of psoriasis was similar to that of Acitretin capsules,
5 but there was less side effects appeared in Yinxieling tablet group²⁰. In Dai's study, 90
6 patients in observation groups were treated with Yinxieling and 30 patients in control
7 group were treated by placebo for 8 weeks. The result showed that
8 Yinxieling decoction had therapeutical effect on psoriasis vulgaris²¹. However, there
9 are limitations in the further development of Yinxieling because its
10 complex compounds.

11 In order to expand the application of Yinxieling, an optimized formula PSORI-CM01
12 (former name YXBCM01) was developed, composed of only seven ingredients (radix
13 paeoniae rubra, *smoked plum*, *chloranthus spicatus*, *radices lithospermi*, *curcuma*
14 *zedoary*, *rhizome smilacis glabrae*, *liquorice*) of Yinxieling tablet which were found
15 to have positive correlations with pharmacodynamic indicators by using computer
16 systematic pharmacological method and orthogonal experiments^{22, 23}. An
17 observational study showed two months treatment of PSORI-CM01 for psoriasis
18 vulgaris reduced PASI and DLQI scores with no adverse event²⁴. Another 12-week
19 observational study showed the PASI of patients with psoriasis reduced after
20 PSORI-CM01 treatment and the metabolic variations visualized in patients with
21 psoriasis before and after PSORI-CM01 treatment²⁵.

22 However, previous studies of PSORI-CM01 are all based on preliminary clinical
23 observation. Whether clinical efficacy and safety of PSORI-CM01 granule are better
24 than its prototype Yinxieling tablet or not is still uncertain. Therefore, a rigorously
25 designed randomized controlled trial to determine PSORI-CM01 is more effective
26 than Yinxieling tablet and to investigate the efficacy and safety of this new formula is
27 warranted.

28 **Method**

29 **Design**

30 This is a double-dummy double-blind randomized controlled trial to investigate the
31 efficacy and safety of the new formula PSORI-CM01 granule compared with its
32 prototype Yinxieling tablet. This study will be performed in three centers in China:
33 Guangdong Provincial Hospital of Chinese Medicine, Affiliated Hospital of Tianjin
34 Chinese Medicine Academy and The Third Hospital of Hangzhou. Because Yinxieling
35 tablet and PSORI-CM01 granules are in different preparation form, a double-dummy
36 double-blind trial design was determined in order to guarantee rigorous blinding.

37 The study procedure consists of three components, initial screening, treatment period,
38 and follow-up period, respectively. In the initial screening, patients with psoriasis will
39 be recruited via dermatology clinic for physical examination and inclusion assessment.
40 A two-week run-in period may be asked depending on the result of the assessment. If
41 eligible, informed consent will be presented to the participant to sign on. All details in
42 the informed consent will be clearly explained to the participant to assure their
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 understanding. Once informed consent is obtained, a participant will be given a
4 random sequence number. All participants will be allocated into two groups with a
5 ratio of 1:1. One group receives PSORI-CM01 granules with Yinxieling placebo
6 tablet, while the other group Yinxieling tablet with PSORI-CM01 placebo granules
7 (Fig. 1).
8

9
10 The trial protocol was approved by the Guangdong Provincial Hospital of Chinese
11 Medicine ethics committee, and registered with the Chinese Clinical Trial Registry
12 (ChiCTR-TRC-14005185).
13

14 15 **Eligibility criteria**

16 **Inclusion criteria**

17 Patients must meet all of the following criteria at the time of randomisation to be
18 eligible for recruitment:
19

- 20 (1) In accordance with the diagnosis of psoriasis vulgaris referring to the "Clinical
21 Guidelines of Psoriasis 2008" reported by the Chinese Medical Association²⁶;
- 22 (2) male or female patient between 18 to 65 years old;
- 23 (3) PASI more than 3 and less than 30, and BSA less than 30%;
- 24 (4) Informed consent.

25 **Exclusion criteria**

26 The trial exclusion criteria include any of the following:
27

- 28 (1) Psoriatic lesions can only be seen on face, scalp, nails, balanus, mucus and
29 palmarplantar areas;
- 30 (2) Acute progressive psoriasis, and erythroderma tendency;
- 31 (3) Pregnant, lactating, or those who plan to become pregnant in a year; (4) SAS more
32 than 50 or SDS more than 53, or with other psychiatric disorders;
- 33 (5) With history of primary cardiovascular, respiratory, digestive, urinary,
34 endocrinologic and hematologic diseases, which cannot be controlled through
35 ordinary treatments. Those who with malignant diseases, infections, electrolyte
36 imbalance, acid-base disturbance. Patients with clinical test results listed below: AST
37 or ALT 3 times more than normal upper limit; Creatinine 1.5 times more than normal
38 upper limit; Hemoglobin elevates 20g/L more than normal upper limit; Platelet count
39 less than $75.0 \times 10^9/L$; White blood cell less than $3.0 \times 10^9/L$; Or any other abnormal
40 laboratory test results, assessed by investigators, that are not suitable for this clinical
41 study;
- 42 (6) Allergic to any medicine or ingredients used in this study;
- 43 (7) Participating other clinical trials or participated within 1 month.
- 44 (8) Obtained corticosteroids or Retinoic acid acting on the skin over the previous 2
45 weeks; systemic therapy or phototherapy (UVB and PUVA) over the previous 4
46 weeks; biological therapy over the previous 12 weeks.
- 47 (9) Patients need systemic treatment with western medicine.
48
49
50
51
52
53
54
55
56
57
58
59
60

Interventions

PSORI-CM01 group

Participants in PSORI-CM01 group will receive PSORI-CM01 granules 5.5 g twice daily after meals and five placebo tablets three times daily after meals for 12 weeks.

Yinxieling group

Participants in Yinxieling group will receive five Yinxieling tablets three times daily after meals and placebo granules 5.5 g twice daily after meals for 12 weeks.

Outcome measures

Primary outcome

The primary outcome is reduction of PASI score. PASI score of patients will be assessed every 2 weeks during the treatment period and every 4 weeks in the follow-up period. Target lesions will be recorded as digital photo by SLR cameras in every visit.

Secondary outcomes

Secondary outcome measure include relapse rate, BSA, VAS and DLQI. The VAS and BSA will be assessed every 2 weeks during the treatment period and every 4 weeks in the follow-up period. The DLQI will be assessed by patients every 4 weeks during the treatment period. In follow-up period DLQI will only be assessed on the last week (the 24th week). Laboratory reports were also monitored until the last visit (Tab. 1).

Health economics

Economic evaluation will be carried out from Health Department of Guangdong Province perspective, which will be in form of cost-utility analysis and conducted using utility values obtained from the DLQI preference-based quality of life measure. DLQI is a dermatology-specific Quality of Life instrument for routine clinical use. It is a validated questionnaire with simple 10-question. At present the DLQI is the most frequently used instrument for evaluating the impact of skin disease and related treatment on patients' lives. DLQI will be measured at baseline and at 4 and 16 weeks for utility-based quality of life evaluation in this study. Resource use will include intervention costs, healthcare costs and community service costs, which will be calculated for each trial participant. We will analyze an incremental cost-effectiveness ratio (ICER) of cost per patient by calculating the incremental mean difference in costs between the two trial arms and incremental difference in patient outcome after

1
2
3 the follow-up.
4
5

6 7 **Sample size**

8 Since there is lacking of studies evaluating the effect of PSORI-CM01 granule or
9 Yingxieling tablet on psoriasis for sample size calculation, we based on the previous
10 study results and experts' opinions to assume the sample size using PASW Statistics
11 software (version 18.0; IBM Inc., Chicago, IL, USA): Assumed that compare with
12 Yingxieling tablet, the effective of PSORI-CM01 granule with an expected PASI
13 improvement growth more than 1.5 is expected. Group sample sizes of 236 and 236
14 achieve 80% power to detect superiority using a one-sided, two-sample t-test. The
15 margin of equivalence is . The true difference between the means is assumed to be 1.5.
16 The significance level (alpha) of the test is 0.025. The data are drawn from
17 populations with standard deviations of 1.1 and 2.5. Considering 15% loss to
18 follow-up, 278 patients are needed in each arm, totaling 556 patients in all.
19
20
21
22
23
24
25
26
27

28 29 **Randomisation and allocation**

30 Eligible patients will be randomly assigned, in a 1:1 ratio, to one of the two treatment
31 groups (PSORI-CM01 group or Yinxieling group) at the second visit through central
32 randomization. Equal randomization will be conducted using a computer-generated
33 random allocation sequence through the stratified block randomization method of the
34 SAS software (version 9.12; SAS Institute, Inc., Cary, NC, USA) by the Key Unit of
35 Methodology in Clinical Research (KUMCR) of Guangdong Provincial Hospital of
36 Chinese Medicine. Allocation concealment will be ensured, as the randomization code
37 will be released by the Interactive Web Response System for Chinese Medicine Trials
38 (IWRS-CMT), which was a verified online randomization facility established by the
39 KUMCR (<http://www.gzctcmgcp.net/sjxt/login.asp>). After that, the participants will
40 be randomly allocated to two different treating groups.
41
42
43
44
45
46
47
48

49 50 **Test drugs and blinding**

51 After the preliminary clinical observation, we changed the form of PSORI-CM01
52 formula to granules considering the preparation of oral granules is normally smooth,
53 quick water absorption and swelling properties that allow easy swallowing.
54

55 The PSORI-CM01 granules and the matching placebo granules used in the trial were
56 prepared by Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, Jiangsu Province, China),
57
58
59
60

1
2
3 Yinxieling tablets and the matching placebo tablets were prepared by Kangyuan
4 Pharmaceutical Co., Ltd. (Guangzhou, Guangdong Province, China). All drugs above
5 met the requirements of the Good Manufacturing Practice (GMP). The main
6 ingredients of placebo granules and placebo tablets are maltodextrin, lactose, and a
7 natural edible pigment, will be similar to the PSORI-CM01 granules and Yinxieling
8 tablets in appearance, weight, and taste.

9
10
11
12 The practitioners will be blind to the allocation arm according to the similar medical
13 procedures. And the evaluation of participants and the analysis of the results will be
14 performed by physician assessors and statisticians who are blinded to the group
15 allocation.
16
17
18
19

20 21 22 **Statistical analysis**

23 All analyses will be performed with PASW Statistics and SAS 9.2 software by a
24 statistician who is blinded to the random allocation of groups. Intent-to-treat (ITT)
25 basis statistical analysis with a 95% confidence interval will be performed. The ITT
26 analysis will include all patients who are randomized²⁷. Safety analysis will be
27 undertaken by analyzing the frequency of adverse events which are suspected as
28 related to the treatment. The various parameters observed were compared using
29 Chi-square test for non-continuous variables (i.e. the primary outcome relapse rate)
30 and t-test and analysis of variance (ANOVA) for continuous variables. In order to
31 distinguish the treatment effect and time effect, the repeated measures analysis of
32 variance change from baseline will be performed for the different time point
33 assessments. Statistical significance was established at $P < 0.05$.
34
35
36
37
38
39
40
41

42 **Adverse events**

43 Before the beginning and after the 12 weeks treatment, a medical history will be
44 recorded for each patient, and standard laboratory examinations and specific
45 laboratory investigations are also performed. The standard laboratory examinations
46 including: hematologic parameter assessment (hemoglobin, red blood cell, platelet,
47 and white blood cell counts); urinalysis (proteins, red blood cell, and white blood cell
48 biochemical assessment (serum electrolytes); indices of renal function (creatinine,
49 urea) and hepatic function (alkaline phosphatase, aspartate amino transferase, alanine
50 amino transferase, and g-glutamyl-trans-peptidase); and electrocardiogram. The
51 specific laboratory investigations mainly include serum cytokine levels.
52
53
54
55
56
57
58
59
60

All adverse events will be collected and graded for severity and potential relation to

1
2
3 the treatments in the study by assessors at every visit. Safety evaluations included the
4 incidence of treatment-induced or serious adverse events, dropout because of adverse
5 events, and changes from baseline of PASI score and laboratory parameters. In case of
6 severe adverse effects, all the drugs for this trial will be discontinued immediately.
7
8
9

10 **Data management**

11 All physicians, assessors and research assistants will attend training workshops before
12 the conduction of trial. Investigators in different centers are all required to follow the
13 standard operating procedures. The quality controllers from CRO (contract research
14 organization) company will perform a regularly monitoring in each centre throughout
15 the trial. All study data will be managed as detailed in the full trial protocol and in
16 accordance with the data management plan which have been developed by Data
17 Monitoring Committee of GPHCM (Guangdong Provincial Hospital of Chinese
18 Medicine). The data collection included all information of case report forms. Data
19 will be entered using the double entry method. To make sure data quality and
20 data consistency between source data and data entered in the database, two research
21 assistants will independently input the data from CRFs to data base by using a
22 prespecified database software which have been developed by Data Monitoring
23 Committee. The Data Monitoring Committee will assess the safety data and the
24 critical efficacy outcomes after the trial is finished.
25
26
27
28
29
30
31
32
33
34
35

36 **Discussion**

37 Psoriasis is an immune-abnormal disease that progresses slowly over a long period
38 with frequent symptoms recurrence. Psoriasis causes detrimental effects on the quality
39 of life both in adults and children. Elevated rates of various psychopathologies,
40 including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal
41 ideation have been reported in patients with psoriasis²⁸⁻³². Psoriasis is not a disease
42 affecting the skin only. Increasing evidence support the recognition of psoriasis as a
43 chronic multisystem inflammation disorder with multiple associated comorbid
44 conditions. Comorbidities linked to psoriasis include psoriatic arthritis, cardiovascular
45 diseases, obesity, metabolic syndrome, malignancy, hypertension, inflammatory
46 bowel disease²⁵. Psoriatic arthritis (PsA) is an erosive and deforming joint disease
47 associated with psoriasis that affect 7% to 42% of the psoriasis population³³.
48 PsA-induced joint damaging complications not only lead to lower articular function
49 and higher mortality but also affect patients' ability to work and affect their social
50
51
52
53
54
55
56
57
58
59
60

relationships³⁴. In patient with severely affected psoriasis, a 5-year shorter life expectancy tends to happen among them, mostly due to cardiovascular disease³⁴. What's more, psoriasis has strong connection with metabolic syndrome, making it a marker for increased risk for the morbidity and mortality associated with these diseases³⁵.

Treatments used for moderate-to-severe psoriasis (phototherapy, oral systemic, or biologic therapies) were received by 27.3% of the total psoriasis sample, of whom 37.2% used biologics³⁶. Orally administered Chinese herbal medicine has been used for the clinical management of psoriasis for years. However, a number of high-quality clinical trials are needed before Chinese herbal medicine can be recommended for psoriasis. We conducted a series of systematic reviews to evaluate the effects of Chinese herbal medicine alone or in combination with pharmacotherapy for psoriasis⁹⁻¹⁷. The results showed that there is promising evidence of positive effects in a number of the studies of multi-herb formulations. And the most frequently used herbs for psoriasis in clinical trials were *angelica sinensis*, *rehmannia glutinosa*, *smilax glabra*, *paeonia veitchii*, *lithospermum erythrorhizon* and *salvia miltiorrhiza*. Most of them were compositions of the prescription in PSORI-CM01 formula.

We changed the form of PSORI-CM01 formula to granules in this study. Tablets containing micronized Chinese herbal medicine are not suitable for immediate release. Granules are solid when stored and that will swell and gel via water absorption. What's more, granules from simplified formulations offer great opportunities to improve continuous processes, present performances comparable to more complicated formulations and are able to correspond to requirements of the authorities. In this study, the micro-structure and tensile strength of the granules resembled that of tablets formed from the original ungranulated powder.

To our knowledge, this trial is the first study to compare the clinical effectiveness of Chinese medicine treatment for psoriasis before and after optimization and simplification. And we aim to provide supportive data for the effectiveness of PSORI-CM01 granule which is from the optimization of Yinxieling tablet determined in the previous study and clinical practice. This study is the third clinical trial which our research team has conducted on the effectiveness of PSORI-CM01 granule on patients with psoriasis. The first study was comparing oral PSORI-CM01 granule plus topical sequential therapy for moderate-to-severe psoriasis, which was a double-blind, randomized placebo controlled trial to evaluate the effectiveness of PSORI-CM01 combined with usual topical therapy compared to usual topical therapy in the clinical practice of Western medicine alone^{37, 38}. The second study was evaluating oral

1
2
3 PSORI-CM01 granule plus topical calcipotriol for psoriasis comparing with placebo
4 plus topical calcipotriol for 12 weeks, which was a pilot randomized, placebo
5 controlled, double-blinded trial³⁹. These two trials aimed to evaluate the benefit of
6 adding PSORI-CM01 granule to conventional treatments when treating psoriasis.
7 Different from the above two trials, this clinical trial protocol acts as the foundation
8 for evaluating Chinese medicine treatment on psoriasis.
9

10
11 For facilitating appropriate reference standards for scientific, ethical and safety issues
12 before the trial begins, this protocol has been developed according to Standard
13 Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 and
14 Consolidated Standards of Reporting Trials (CONSORT) statement^{40, 41}.
15
16

17 18 19 **Trial status**

20
21 The recruitment phase began in November 2014. And so far 53 patients were
22 recruited.
23

24 25 **Abbreviations**

26 ANOVA: Analysis of variance

27 BSA: Body Surface Area

28 CRO: contract research organization

29 DLQI: Dermatology Life Quality Index

30 ITT: Intent-to-treat

31 IWRS-CMT: Interactive Web Response System for Chinese Medicine Trials

32 KUMCR: Key Unit of Methodology in Clinical Research

33 PASI: Psoriasis Area and Severity Index score

34 SAS: Self-rating Anxiety Scale

35 SDS: Self-rating Depression Scale

36 VAS: Visual analogue scale
37
38
39
40
41
42
43
44
45

46 **Competing interest**

47 The authors declare that they have no competing interests.
48
49

50 **Authors' contributions**

51 Jingwen Deng, Danni Yao and Chuanjian Lu drafted the manuscript. Chuanjian Lu
52 and Zehuai Wen participated in the design of the study, Danni Yao, Yuhong Yan,
53 Ziyang He, Huimei Wu and Hao Deng coordinate the study. All authors participated
54 in, read, and approved the final manuscript.
55
56
57
58
59
60

Acknowledgments

This research was supported by grants of the National Key Technology R&D Program for the 12th Five-year Plan of Ministry of Science and Technology, China (No. 2013BAI02B03), Provincial Science and Technology Project of Guangdong Province, China (No.2015B020211013) and Guangdong Provincial Bureau of traditional Chinese Medicine Research Project (No.20161110).

We thank Prof. Guo-Wei Xuan (Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China), Profs. Ai-E Xu and Jun-Jun Shan (The Third Hospital of Hangzhou, Hangzhou, China), Profs. Jun-ling Zhang and Hong-mei Wang (Affiliated Hospital of Tianjin Chinese Medicine Academy) for their suggestions. We also thank Mr Wen-Wei Ouyang and Dr Li-Ming Lu (Guangdong Provincial Hospital of Chinese Medicine) for comments and suggestions on data management and the statistical analysis plan.

References

1. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2009. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2009.
2. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annu Rev Pathol*. 2012;7:385–422.
3. Ben Salem C, Hmouda H, Bouraoui K. Psoriasis. *The New England journal of medicine*. 2009 Oct 22;361(17):1710
4. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. *Molecular immunology*. 2015 Apr;64(2):313-23.
5. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *The Journal of investigative dermatology*. 2013 Feb;133(2):377-85.
6. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007 Jul 21;370(9583):263-71.
7. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. *Journal of the American Academy of Dermatology*. 2015 Apr 14.
8. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). *Archives of dermatological research*. 2012 Mar;304(2):87-113.
9. Zhang CS, Yang L, Zhang AL, May BH, Yu JJ, Guo X. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. *J Altern Complement Med*. 2016 Mar;22(3):174-88.
10. May BH, Zhang AL, Zhou W, Lu CJ, Deng S, Xue CC. Oral herbal medicines for psoriasis: a review of clinical studies. *Chin J Integr Med*. 2012;18:172-8.
11. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, et al. Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. *Int J Dermatol*. 2014;53(11):1305–18.
12. Deng S, May BH, Zhang AL, Lu C, Xue CC. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. *Br J Dermatol*. 2013 Oct;169(4):769-82.
13. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal formulae in the management of psoriasis: systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs. *Phytother Res*. 2014 Apr;28(4):480-97.
14. Yang L, Zhang CS, May B, Yu J, Guo X, Zhang AL, et al. Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a

- 1
2
3 systematic review and meta-analysis. *Chin Med*. 2015 Sep 26;10:27.
- 4
5 15. Deng S, May BH, Zhang AL, Lu C, Xue CC. Phytotherapy in the management of
6
7 psoriasis: a review of the efficacy and safety of oral interventions and the
8
9 pharmacological actions of the main plants. *Arch Dermatol Res*. 2014
10
11 Apr;306(3):211-29.
- 12
13 16. Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C. Add-on effect of chinese
14
15 herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review. *Evid
16
17 Based Complement Alternat Med*. 2013;2013:673078.
- 18
19 17. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal medicine combined
20
21 with pharmacotherapy for psoriasis: a systematic review and meta-analysis. *Arch
22
23 Dermatol Res*. 2013 Apr;305(3):179-89.
- 24
25 18. Han L, Peng Y, Zhao RZ, Feng B, Lu CJ. Effect of Yinxieling on proliferation of
26
27 HaCaT. *J Guanghou Univ TCM* 2011; 28(2): 159-162.
- 28
29 19. Lu CZ, Wu XX, Liu FN. Effect of Yinxieling on PCNA expression and apoptosis
30
31 of keratinocyte. *Trad Chin Drug Res Clin Pharmacol* 2006; 17(5): 329-331.
- 32
33 20. Lei Wang, Yongjing, Huang, Minghua Wang. Clinical Observation of Yinxieling
34
35 Tablets for the Treatment of Psoriasis Vulgaris. *Journal of Guangzhou University of
36
37 Traditional Chinese Medicine*. 2009 Nov; 26(6): 520-5.
- 38
39 21. Dai YJ, Li YY, Zeng HM, Liang XA, Xie ZJ, Zheng ZA. Effect of Yinxieling
40
41 decoction on PASI, TNF- α and IL-8 in patients with psoriasis vulgaris. *Asian Pac J
42
43 Trop Med*. 2014 Aug;7(8):668-70.
- 44
45 22. Yan YH, Zhao RZ, Lu CJ. Optimization of Yinxieling Capsule with orthogonal
46
47 design. *Lishizhen Medicine and Materia Medica Research*. 2014; 25(11): 2763-5.
- 48
49 23. Wei Zhu, He Songmin, Yuan Xiaohong, Lu Chuanjian. Computerized Systematic
50
51 Pharmacological Research of Yinxieling Formula. *Traditional Chinese Drug Research
52
53 and Clinical Pharmacology*. 2011; 22(4): 379-82.
- 54
55 24. Yan YH, Lu CJ. Effect of modified Yinxieling on pustular psoriasis. *Trad Chin
56
57 Drug Res Clin Pharmacol* 2011; 22(6): 691-3.
- 58
59 25. Lu C, Deng J, Li L, Wang D, Li G. Application of metabolomics on diagnosis and
60
61 treatment of patients with psoriasis in traditional Chinese medicine. *Biochim Biophys
62
63 Acta*. 2014 Jan;1844(1 Pt B):280-8.
- 64
65 26. Psoriasis Group of Dermatology and Venereology: Chinese Medical Association.
66
67 Clinical guidelines of psoriasis 2008. *Chin J Dermatol (Chin)*. 2009,42, 213-4.
- 68
69 27. Sedgwick P: What is intention to treat analysis? *BMJ* 2013, 346: f3662–f3662.
- 70
71 28. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden

- of psoriasis. *American journal of clinical dermatology*. 2005;6(6):383-92.
29. Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. *Journal of the American Academy of Dermatology*. 2012 Oct;67(4):651-7.
30. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. *The Australasian journal of dermatology*. 2004 Aug;45(3):155-9.
31. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. *Sleep medicine*. 2012 Mar;13(3):285-9.
32. Farley E, Menter A. Psoriasis: comorbidities and associations. *Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia*. 2011 Feb;146(1):9-15.
33. Slobodin G, Rosner I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic arthropathy: where now? *The Israel Medical Association journal : IMAJ*. 2009 Jul;11(7):430-4.
34. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *The British journal of dermatology*. 2010 Sep;163(3):586-92.
35. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications. *Journal of medicine and life*. 2014 Oct-Dec;7(4):468-71.
36. Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, et al. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. *J Invest Dermatol*. 2015 Dec;135(12):2955-63.
37. Wen ZH, Xuan ML, Yan YH, Li XY, Yao DN, Li G. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. *Trials*. 2014 Jul 22;15:294.
38. Yao DN, Lu CJ, Wen ZH, Yan YH, Xuan ML, Li XY, Li G, et al. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. *Trials*. 2016 Mar 16;17(1):140.
39. Parker S, Zhang AL, Zhang CS, Goodman G, Wen Z, Lu C. Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris:

1
2
3 study protocol for a double-blind, randomized placebo controlled trial. *Trials*. 2014
4 Dec 19;15:495.

5
6
7 40. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K,
8 Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR,
9 Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D.
10 SPIRIT: Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern*
11 *Med* 2013, 2013:200–207.

12
13
14 41. Moher D, Schulz KF, Altman DG: CONSORT. The CONSORT statement: revised
15 recommendations for improving the quality of reports of parallel group randomized
16 trials. *BMC Med Res Methodol* 2001, 1:2.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of the study.

BMJ Open: first published as 10.1136/bmjopen-2016-014475 on 3 November 2017. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1 Schedule for treatment and outcome measurements

	Period Time points	Enrolment	Allocation	Treatment period						Follow-up period			
		-1w	0w	2w	4w	6w	8w	10w	12w	16w	20w	24w	
Enrolment	Eligibility screening	●											
	Informed consent	●											
	Characteristic	●											
	Medical history	●											
	Laboratory examination		●						●				
	Biological specimens		●						●				
	Random allocation		●										
Intervention	PSORI-CM01 granules and placebo tablets		☆	—————						☆			
	Yinxieling tablets and placebo granules		★	—————						★			
Assessment	CM syndrome		●						●			●	
	PASI	●		●	●	●	●	●	●	●	●	●	
	BSA	●		●	●	●	●	●	●	●	●	●	
	VAS		●	●	●	●	●	●	●	●	●	●	
	DLQI		●						●			●	
	SAS	●											
	SDS	●											
	Safety assessment			●	●	●	●	●	●	●	●	●	

☆: For PSORI-CM01 group

★: For Yinxieling group



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	7, Table.1
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	7-8
	7b	When applicable, explanation of any interim analyses and stopping guidelines	9
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	9
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	9
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and	9
10	diagram is strongly	were analysed for the primary outcome	
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons	
12	Recruitment	14a Dates defining the periods of recruitment and follow-up	12
13		14b Why the trial ended or was stopped	
14	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	
15	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was	
16		by original assigned groups	
17	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	
18	estimation	precision (such as 95% confidence interval)	
19		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
20	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
21		pre-specified from exploratory	
22	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
23			
24	Discussion		
25	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
26	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	
27	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
28			
29	Other information		
30	Registration	23 Registration number and name of trial registry	1
31	Protocol	24 Where the full trial protocol can be accessed, if available	
32	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	12
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

BMJ Open

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol for a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014475.R1
Article Type:	Protocol
Date Submitted by the Author:	24-May-2017
Complete List of Authors:	Deng, Jingwen; Dermatology Yao, Danni; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Lu, Chuan-jian ; Guangdong Provincial Hospital of Traditional Chinese Medicine, Department of dermatology Wen, Zehuai; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Yan, YuHong; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology He, Ziyang; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Wu, Huimei; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Deng, Hao; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, Chinese medicine, Clinical Trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol for a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Jingwen Deng^{1,2,†}, Danni Yao^{1,2,†}, Chuanjian Lu^{1,2,3*}, Zehuai Wen⁴,
Yuhong Yan^{1,2}, Ziyang He¹, Huimei Wu^{1,2}, Hao Deng^{1,2}

Abstract

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Introduction: Psoriasis vulgaris (PV) is a common skin disease that is characterized by persistent localized erythematous scaly plaques. Yinxieling is a Chinese herbal formula for psoriasis that has been used for more than 20 years in China. To facilitate application, PSORI-CM01 was developed based on the optimization and simplification of Yinxieling tablets performed in a previous study and in clinical practice. However, the scientific evidence regarding whether PSORI-CM01 is more effective for psoriasis than the original Yinxieling remains insufficient. Therefore, we designed a randomized clinical trial to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granules compared with those of Yinxieling tablets for the treatment of patients with psoriasis.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Methods and analysis: This on-going study is a two-arm parallel, randomized, double-blind, double-dummy clinical trial. Five hundred fifty-six participants with psoriasis will be recruited and then randomly allocated into two groups in a 1:1 ratio. Participants in PSORI-CM01 group will receive a 5.5-g granule of PSORI-CM01 twice daily and five placebo tablets three times daily for 12 weeks. The participants in the Yinxieling group will receive five Yinxieling tablets three times daily and a placebo granule twice daily for 12 weeks. The primary outcome is the reduction of the Psoriasis Area and Severity Index (PASI). The secondary outcomes include relapse rate, visual analogue scale (VAS) scores, body surface area (BSA), and the Dermatology Life Quality Index (DLQI). Cost effectiveness analysis will be performed from a health and community care provider perspective.

47
48
49
50
51
52
53
54
55

Ethics and dissemination: This research protocol had been reviewed and approved by the institutional review boards of three trial centres (Guangdong Provincial Hospital of Chinese Medicine (B2014-026-01), Affiliated Hospital of Tianjin Chinese Medicine Academy (2014-KY-001) and Third Hospital of Hangzhou (B2014-026-01)). The findings will be disseminated to the public through conference presentations and open access journals.

56
57

Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-14005185

58
59

[†]Jingwen Deng and Danni Yao contributed equally to this work.

60
1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*** Correspondence:**

Chuanjian Lu

luchuanjian888@vip.sina.com

Strengths and limitations of this study

- We are performing a trial to provide evidence regarding the clinical effectiveness of a Chinese medicine treatment for psoriasis before and after optimization and simplification. There is no absolute placebo control, which means that this trial will be unable to assess the absolute efficacy and will assess only the relative efficacy.
- Participants will be randomized to either a PSORI-CM01 granule with Yinxieling placebo tablet group or a Yinxieling tablet with PSORI-CM01 placebo granule group. The primary outcome is the reduction of the PASI score at week 12.
- For broad use of the herbal formula, we designed PSORI-CM01 based on the rule “treated from the blood”, which is related to the core pathogenesis of psoriasis in Traditional Chinese Medicine (TCM) theory. This formula can be applied to the blood heat, blood stasis, and blood dryness syndromes of psoriasis. Therefore, there is no stratification based on TCM syndromes in the design of the trial.

Authors' information

1. Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China;
2. Psoriasis clinical and basic research team, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou 510120, China;
3. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 510120, China
4. Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Authors' contact information

JingWen Deng, e-mail: s6891@163.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

DanNi Yao, e-mail: yaodanni1984@163.com,

Tel:+8620-81887233-30603, Fax:+8620-81874903

ChuanJian Lu, e-mail: luchuanjian888@vip.sina.com

Tel:+8620-81887233-31223, Fax:+8620-81874903

ZeHuai Wen, e-mail: wenzh@gzucm.edu.cn,

2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tel:+8620-81887233-31227, Fax:+8620-81874903

YuHong Yan, e-mail: yanyuhong7966@139.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

ZiYang He, e-mail: ziyanghe@qq.com,

Tel:+8620-81887233-31227, Fax:+8620-81874903

HuiMei Wu, e-mail: 691892927@qq.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

Hao Deng, e-mail: 563435624@qq.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

For peer review only

Background:

Psoriasis is a chronic, immune-mediated, inflammatory skin disease characterized by erythema, scale and redness, and thickening and scaling of the skin. The main histopathologic change of psoriasis is accelerated keratinocyte cell proliferation^{1, 2}. However, the cause of this disease remains unknown. Although an early concept of the pathogenesis of psoriasis focused on the proliferation and differentiation of keratinocytes, recent studies have recognized that dysregulation of the immune system plays a critical role in the development of psoriasis. The interactions between dendritic cells, T cells, keratinocytes, neutrophils, and the cytokines released from immune cells are the core mechanism of the development of psoriasis³. Genetic, environmental and behavioural factors are thought to be triggers that contribute to the onset of psoriasis⁴. The prevalence of psoriasis in adults is estimated to range from 0.91% to 8.5% worldwide⁵. Clinically, psoriasis vulgaris is the most common subtype of psoriasis and affects approximately 90% of patients⁶.

The most common treatments for psoriasis include topical medication, ultraviolet light, systematic drugs and biologics. Topical medications, such as corticosteroids, retinoid and vitamin D analogues, are considered to be first-line therapies for psoriasis vulgaris. Systematic drugs are for severe psoriasis, while ultraviolet light and biologics are used when applicable and necessary⁷.

A series of systematic reviews have demonstrated that Chinese Medicine contains an effective therapy for psoriasis⁸⁻¹⁶. Yinxieling tablets, which are a Chinese herbal medicine compound preparation with 10 ingredients (i.e., *angelica sinensis*, *radix paeoniae rubra*, *chloanthus spicatus*, *smoked plum*, *radix rehmanniae recen*, *ligusticum wallichii*, *radices lithospermi*, *curcuma zedoary*, and *rhizome smilacis glabrae*, *liquorice*) that is used for the treatment of psoriasis, was developed by the National Medical Master Guo-wei Xuan, who is a well-known Chinese medicine doctor. These tablets were formulated according to traditional Chinese medicine theory and are theoretically effective and safe. In TCM theory, three syndromes of psoriasis are generally acknowledged: blood stasis, blood heat, and blood dryness type. In the acute stage, the pathogenesis of psoriasis vulgaris is mostly blood heat that is obstructed on the surface of the skin. In the chronic stage, the pathogenesis of psoriasis vulgaris is blood deficiency that develops into dryness that prohibits the nourishing of the skin or blood stasis that obstructs blood flow in skin collaterals. Therefore, activating blood circulation and removing blood stasis should be the focus of curing of psoriasis. Yinxieling tablets play the role of activating blood circulation and removing blood stasis in the treatment of psoriasis¹⁷.

In the recent 20 years of clinical practice, Yinxieling tablets have been extensively used for the treatment of psoriasis and have exhibited a promising clinical efficacy in terms of relieving the symptoms of psoriasis and reducing the relapsing rate. Molecular biological technologies have been used to analyse the pharmacological

1
2
3 mechanisms of multiple ingredients in Yinxieling tablets^{18, 19}. These studies have
4 demonstrated that Yinxieling tablets are involved in the regulation of
5 immune-mediated cells and the interaction of cellular cytokines, which has revealed
6 the potential mechanism of Yinxieling tablets in the treatment of psoriasis. In the
7 exploration of the molecular and pharmacological mechanisms of Yinxieling tablets,
8 two clinical trials have been performed to confirm their clinical effectiveness. In
9 Wang's study, 24 patients with psoriasis were equally randomized into the following
10 two groups: a treatment group that received Yinxieling tablets for eight weeks and a
11 control group that received acitretin capsules for eight weeks. The therapeutic effect
12 of the Yinxieling tablets in the treatment of psoriasis was similar to that of the
13 acitretin capsules, but fewer side effects appeared in the Yinxieling tablet group²⁰. In
14 Dai's study, 90 patients in observation groups were treated with Yinxieling, and
15 30 patients in a control group were treated with placebo for 8 weeks. The result
16 revealed that the Yinxieling decoction had a therapeutic effect on psoriasis vulgaris²¹.
17 However, there are limitations to the further development of Yinxieling because of its
18 complex compounds.

19 To expand the application of Yinxieling, an optimized formula, i.e., PSORI-CM01
20 (former name YXBCM01), was developed. This formula is composed of only seven
21 ingredients (i.e., *radix paeoniae rubra*, *smoked plum*, *chloranthus spicatus*, *radices*
22 *lithospermi*, *curcuma zedoary*, *rhizome smilacis glabrae*, and *liquorice*) of the
23 Yinxieling tablet that were found to have positive correlations with pharmacodynamic
24 indicators based on a computerized systematic pharmacological method and
25 orthogonal experiments^{22, 23}. An observational study revealed that two months of
26 treatment with PSORI-CM01 for psoriasis vulgaris reduced the PASI and DLQI
27 scores with no adverse events²⁴. Another 12-week observational study revealed that
28 the PASIs of patients with psoriasis were reduced after PSORI-CM01 treatment, and
29 the metabolic variations were observed in patients with psoriasis before and after
30 PSORI-CM01 treatment²⁵. Our previous study demonstrated that PSORI-CM01 can
31 reduce keratinocyte proliferation in vitro and inhibit epidermal hyperplasia in an
32 imiquimod (IMQ)-induced psoriasis-form mouse model²⁶. The PSORI-CM01 formula
33 can also affect the IL-17/IL-23 axis and inhibit the expression of cytokines and
34 chemokines and thus improve inflammatory conditions in the dermic
35 microenvironment²⁷.

36 However, the previous studies of PSORI-CM01 are all based on preliminary clinical
37 observations and animal experiments. Whether the clinical efficacy and safety of
38 PSORI-CM01 granules are better than those of its prototype, i.e., the Yinxieling tablet,
39 remains uncertain. Therefore, a rigorously designed randomized controlled trial to
40 determine whether PSORI-CM01 is more effective than the Yinxieling tablet and to
41 investigate the efficacy and safety of this new formula is warranted.

42 Method

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Design

This is a double-dummy, double-blind, randomized, controlled trial to investigate the efficacy and safety of the new formula PSORI-CM01 granule compared with its prototype, the Yinxieling tablet. This study will be performed in three centres in China: the Guangdong Provincial Hospital of Chinese Medicine, the Affiliated Hospital of Tianjin Chinese Medicine Academy, and the Third Hospital of Hangzhou. Because Yinxieling tablets and PSORI-CM01 granules have different preparation forms, a double-dummy, double-blind trial design was selected to guarantee rigorous blinding. The study procedure consists of three components, i.e., an initial screening, a treatment period, and a follow-up period. In the initial screening, patients with psoriasis will be recruited via a dermatology clinic for physical examination and inclusion assessment. A two-week run-in period may be requested depending on the results of the assessments. If eligible, written informed consent will be requested of the participants. Additional consent provisions for collection and use of participant data and biological specimens will be requested as well. All details of the informed consent will be clearly explained to the participant to assure their understanding. Once informed consent is obtained, a participant will be given a random sequence number. All participants will be allocated into two groups at a ratio of 1:1. One group will receive PSORI-CM01 granules with Yinxieling placebo tablets, and the other group will receive Yinxieling tablets with PSORI-CM01 placebo granules (Fig. 1). We will collect patients' information about TCM syndromes before and after the treatment. Target lesions will be recorded with digital photographs taken with SLR cameras at every visit.

The trial protocol was approved by the Guangdong Provincial Hospital of Chinese Medicine ethics committee, and registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-14005185).

Eligibility criteria

Inclusion criteria

The patients must meet all of the following criteria at the time of randomization to be eligible for recruitment:

- (1) The patients must meet the criteria for the diagnosis of psoriasis vulgaris referred to in the Clinical Guidelines of Psoriasis 2008 reported by the Chinese Medical Association²⁸.
- (2) Male and female patients must be between 18 and 65 years old.
- (3) A PASI of more than 3 and less than 30, and a BSA of less than 30% are required.
- (4) Informed consent must be obtained.

Exclusion criteria

The trial exclusion criteria include any of the following:

- (1) Psoriatic lesions can only be seen on the face, scalp, nails, anus, mucus and

palmar-plantar areas.

(2) Acute progressive psoriasis, an erythroderma tendency, and psoriatic arthritis are present.




Figure 1. Flowchart of the study.

(3) Patients who are pregnant, lactating, and those who plan to become pregnant within a year will be excluded.

(4) Those with an SAS more than 50 or an SDS more than 53, and those with other psychiatric disorders will be excluded.

(5) Those with a history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and haematologic diseases that cannot be controlled with ordinary treatments will be excluded. Those with malignant diseases, infections, electrolyte imbalances, and acid-base disturbances will be excluded. Patients with the following clinical test results will be excluded: an AST or ALT 3 times greater than the normal upper limit, creatinine 1.5 times greater than the normal upper limit; haemoglobin elevated by 20 g/L above the normal upper limit; a platelet count less than $75.0 \times 10^9/L$;

a white blood cell count less than $3.0 \times 10^9/L$, and other abnormal laboratory test results, as assessed by the investigators, which are not suitable for this clinical study.

(6) Patients who are allergic to any medicine or ingredients used in this study will be excluded.

(7) Those participating other clinical trials and those who have participated in trials within 1 month will be excluded.

(8) Patients who have used corticosteroids or retinoic acid acting on the skin over the previous 2 weeks, those on systemic therapy or phototherapy (UVB and PUVA) with the previous 4 weeks, and those on biological therapy over the previous 12 weeks will be excluded.

Interventions

PSORI-CM01 group

Participants in PSORI-CM01 group will receive 5.5 PSORI-CM01 granules twice daily after meals and five placebo tablets three times daily after meals for 12 weeks.

Yinxieling group

Participants in Yinxieling group will receive five Yinxieling tablets three times daily after meals and placebo granules 5.5 g twice daily after meals for 12 weeks.

Outcome measures

Primary outcome

The primary outcome is the reduction in the PASI score, which will be calculated as follows:

Reduction of the PASI = PASI at baseline - PASI at week 12.

The PASI scores of the patients will be assessed every 2 weeks during the treatment period and every 4 weeks during the follow-up period. The PASI reduction calculated at week 12 will be considered the primary outcome.

Secondary outcomes

The secondary outcome measures include relapse rate, BSA, VAS and DLQI. The VAS and BSA will be assessed every 2 weeks during the treatment period and every 4 weeks in the follow-up period. The DLQI will be assessed by the patients every 4 weeks during the treatment period. In the follow-up period, the DLQI will only be assessed at the last week (the 24th week). Laboratory reports were also be monitored until the last visit ([Table. 1](#)).

Health economics

An economic evaluation will be performed from the perspective of the Health Department of Guangdong Province and will occur in the form of cost-utility analysis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

and will be conducted using utility values obtained from the DLQI preference-based

For peer review only

Table 1 Schedule for treatment and outcome measurements

	Period Time points	Enrolment	Allocation	Treatment period						Follow-up period			
		-1w	0w	2w	4w	6w	8w	10w	12w	16w	20w	24w	
Enrolment	Eligibility screening	●											
	Informed consent	●											
	Characteristic	●											
	Medical history	●											
	Laboratory examination		●						●				
	Biological specimens		●						●				
	Random allocation		●										
	Intervention	PSORI-CM01 granules and placebo tablets		☆	—————						☆		
Yinxieling tablets and placebo granules			★	—————						★			
Assessment	TCM syndrome		●						●			●	
	PASI	●	●	●	●	●	●	●	●	●	●	●	
	BSA	●	●	●	●	●	●	●	●	●	●	●	
	VAS	●	●	●	●	●	●	●	●	●	●	●	
	DLQI		●						●			●	
	SAS	●											
	SDS	●											
	Safety assessment	●	●	●	●	●	●	●	●	●	●	●	

☆: For PSORI-CM01 group

★: For Yinxieling group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

quality of life measure. The DLQI is a dermatology-specific quality of life instrument for routine clinical use. This instrument is a validated questionnaire with a simple 10-question format. At present, the DLQI is the most frequently used instrument for evaluating the effects of skin disease and related treatments on patients' lives. The DLQI will be measured at baseline and at 4 and 16 weeks for utility-based quality of life evaluation in this study. Resource use will include intervention costs, healthcare costs and community service costs, which will be calculated for each trial participant. We will analyse an incremental cost-effectiveness ratio (ICER) of the cost per patient by calculating the incremental mean difference in costs between the two trial arms and the incremental difference in patient outcome after the follow-up.

Sample size

Due to the lack of studies evaluating the effects of PSORI-CM01 granule and Yinxieling tablets on psoriasis that are available for sample size calculation, we performed the sample calculation based on our previous study's results and experts' opinions²⁹. The superiority-test for two means was used for the sample size calculation. We assumed that the superiority margin of the PASI was 1.5, and the standard deviations were 1.1 and 2.5 for the PSORI-CM01 granules and Yinxieling tablets, respectively. The significance level (alpha) of the test was 0.025, and statistical power was 80%. A sample size of 236 was deemed necessary for the each arm after the calculations. Considering a 15% loss to follow-up, 278 patients are needed in each arm for a total of 556 patients. The PASW Statistics software (version 18.0; IBM Inc., Chicago, IL, USA) was used for the calculations.

Randomisation and allocation

Eligible patients will be randomly assigned, in a 1:1 ratio, to one of the two treatment groups (PSORI-CM01 group or Yinxieling group) at the second visit through central randomization. Equal randomization will be conducted using a computer-generated random allocation sequence through the stratified block randomization method of the SAS software (version 9.12; SAS Institute, Inc., Cary, NC, USA) by the Key Unit of Methodology in Clinical Research (KUMCR) of Guangdong Provincial Hospital of Chinese Medicine. Allocation concealment will be ensured, as the randomization code will be released by the Interactive Web Response System for Chinese Medicine Trials (IWRS-CMT), which was a verified online randomization facility established by the KUMCR (<http://www.gztcmgcp.net/sjxt/login.asp>). After that, the participants will be

1
2
3 randomly allocated to two different treating groups.
4
5

6 7 **Test drugs and blinding**

8 After preliminary clinical observations, we changed the form of the PSORI-CM01
9 formula to granules because the preparation of oral granules normally involves
10 smooth, quick water absorption and swelling properties that allow for easy
11 swallowing.
12

13 The PSORI-CM01 granules and the matching placebo granules used in the trial were
14 prepared by Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, Jiangsu Province, China).
15 The Yinxieling tablets and the matching placebo tablets were prepared by Kangyuan
16 Pharmaceutical Co., Ltd. (Guangzhou, Guangdong Province, China). All of the above
17 drugs met the requirements of Good Manufacturing Practice (GMP). The main
18 ingredients of the placebo granules and the placebo tablets are maltodextrin, lactose,
19 and a natural edible pigment, and these ingredients are similar to those of the
20 PSORI-CM01 granules and Yinxieling tablets in appearance, weight, and taste.
21

22 The practitioners will be blind to the allocation arm, and the arms will have similar
23 medical procedures. Moreover, the evaluations of the participants and the analysis of
24 the results will be performed by physician assessors and statisticians who are blinded
25 to the group allocation.
26
27

28 29 **Statistical analysis**

30 All analyses will be performed with PASW Statistics and SAS 9.2 software by a
31 statistician who is blinded to the random allocation of groups. Intent-to-treat
32 (ITT)-based statistical analyses with 95% confidence intervals will be performed. The
33 ITT analyses will include all of the patients who are randomized³⁰. Safety analysis
34 will be undertaken by analysing the frequency of adverse events that are suspected to
35 be related to the treatment. The various parameters observed will be compared using
36 the chi-square test for non-continuous variables (i.e., the primary outcome and relapse
37 rate), and t-tests and analyses of variance (ANOVAs) will be used for the continuous
38 variables. To distinguish the treatment effect and the time effect, repeated measures
39 analysis of variance of the change from baseline will be performed for the different
40 time point assessments. A subgroup analyses will be performed based on the severity
41 of the disease and the TCM syndromes. Statistical significance will be established at
42 $P < 0.05$.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Adverse events

Before the beginning of, and after 12 weeks of treatment, medical histories will be recorded for each patient, and standard laboratory examinations and specific laboratory investigations will also be performed. The standard laboratory examinations will include the following: haematologic parameter assessment (haemoglobin, and red blood cell, platelet, and white blood cell counts); urinalysis (proteins, and red and white blood cell biochemical assessments (serum electrolytes), indices of renal function (creatinine and urea) and hepatic function (alkaline phosphatase, aspartate amino transferase, alanine amino transferase, and g-glutamyl-transpeptidase); and electrocardiograms. The specific laboratory investigations mainly include the serum cytokine levels.

All adverse events will be collected and graded for severity and potential relation to the treatments by assessors at every visit. The safety evaluations include the incidence of treatment-induced or serious adverse events, dropout due to adverse events, and laboratory parameter changes. In cases of severe adverse effects, all drugs in this trial will be immediately discontinued.

Data management

All physicians, assessors and research assistants will attend training workshops before the conduction of trial. Investigators in different centre will all be required to follow the standard operating procedures. The quality controllers from the contract research organization (CRO) Guangdong International Clinical Research Center of Chinese Medicine (Guangzhou, China) will perform regular monitoring in each centre throughout the trial. All study data will be managed as detailed in the full trial protocol and in accordance with the data management plan, which was developed by the Data Monitoring Committee of the Guangdong Provincial Hospital of Chinese Medicine (GPHCM). The data collection will include all information in the case report forms. The data will be entered using the double entry method. To ensure data quality and data consistency between the source data and the data entered into the database, two research assistants will independently input the data from the CRFs into database using a prespecified database software that was developed by the Data Monitoring Committee. The Data Monitoring Committee will assess the safety data and the critical efficacy outcomes after the trial is finished.

Discussion

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Psoriasis is a disease of immune abnormality that progresses slowly over a long period with frequent symptom recurrences. Psoriasis causes detrimental effects on the quality of life of both adults and children. Elevated rates of various psychopathologies, including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation, have been reported in patients with psoriasis³¹⁻³⁵. Psoriasis is not a disease that only affects the skin. Increasing evidence supports the recognition of psoriasis as a chronic multisystem inflammation disorder with multiple associated comorbid conditions. Comorbidities linked to psoriasis include psoriatic arthritis, cardiovascular diseases, obesity, metabolic syndrome, malignancy, hypertension, and inflammatory bowel disease²⁵. Psoriatic arthritis (PsA) is an erosive and deforming joint disease that is associated with psoriasis and affects 7% to 42% of the psoriasis population³⁶. PsA-induced joint damaging complications not only lead to lower articular function and higher mortality but also affect patients' abilities to work and their social relationships³⁷. In patients with severe psoriasis, the life expectancy is reduced by 5 years primarily due to cardiovascular disease³⁷. Additionally, psoriasis has a strong connection with metabolic syndrome, which makes it a marker for increased risks of the morbidities and mortalities associated with these diseases³⁸. Psoriasis can also cause substantial economic loss. According to a systematic literature review conducted by the American Academy of Dermatology, the total direct and indirect burden of psoriasis is estimated to be \$35.2 billion in the U.S. per annum³⁹.

The treatments used for moderate to severe psoriasis (i.e., phototherapy and oral systemic and biologic therapies) were received by 27.3% of the total psoriasis sample, of whom 37.2% used biologics⁴⁰. Orally administered Chinese herbal medicine has been used for the clinical management of psoriasis for years. However, a number of high-quality clinical trials are needed before Chinese herbal medicine can be recommended for psoriasis. We conducted a series of systematic reviews to evaluate the effects of Chinese herbal medicine alone and in combination with pharmacotherapy for psoriasis⁸⁻¹⁶. The results revealed that there is promising evidence of positive effects from a number of studies of multi-herb formulations.

We changed the form of the PSORI-CM01 formula to granules in this study. Considering too many blood-activating and stasis-dissolving drugs would cause consumption of Qi, we removed *angelica sinensis*, *radix rehmanniae recen*,

1
2
3 *ligusticum wallichii* from Yinxieling. The remain seven herbs turned to be
4 PSORI-CM01. Tablets containing micronized Chinese herbal medicine are not
5 suitable for immediate release. Granules are solid when stored and will swell and gel
6 via water absorption. Additionally, granules from simplified formulations offer great
7 opportunities to improve continuous processes, present performances comparable to
8 more complicated formulations and are able to correspond to the requirements of the
9 authorities. In this study, the micro-structure and tensile strength of the granules
10 resembled those of the tablets formed from the original ungranulated powder.

11 To our knowledge, this trial is the first study to compare the clinical effectiveness of
12 Chinese medicine treatment for psoriasis before and after optimization and
13 simplification. Moreover, we aim to provide supporting data for the effectiveness of
14 the PSORI-CM01 granule that resulted from the optimization of Yinxieling tablet as
15 determined in a previous study and clinical practice. This study is the third clinical
16 trial that our research team has conducted on the effectiveness of the PSORI-CM01
17 granule for patients with psoriasis. The first study compared oral the PSORI-CM01
18 granule plus topical sequential therapy for moderate to severe psoriasis and was a
19 double-blind, randomized placebo-controlled trial that evaluated the effectiveness of
20 PSORI-CM01 combined with usual topical therapy compared with the usual topical
21 therapy that is used in the clinical practice of Western medicine alone^{29, 41}. The second
22 study evaluated oral PSORI-CM01 granule plus topical calcipotriol for psoriasis
23 relative to placebo plus topical calcipotriol over 12 weeks; this study was a pilot
24 randomized, placebo-controlled, double-blinded trial⁴². These two trials aimed to
25 evaluate the benefits of the addition of PSORI-CM01 granules compared with
26 conventional treatments of psoriasis. In contrast to the above two trials, the present
27 clinical trial protocol acts as the foundation for evaluating the treatment of psoriasis
28 with Chinese medicine.

29 For facilitating appropriate reference standards for scientific, ethical and safety issues
30 before the trial begins, this protocol has been developed according to Standard
31 Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 and
32 Consolidated Standards of Reporting Trials (CONSORT) statement^{43, 44}.

33 **Trial status**

34 The recruitment phase began in November 2014. Thus far, 63 patients have been
35 recruited. The estimated end date for this study is in October 2018.

36 **Abbreviations**

37 ANOVA: Analysis of variance

38 BSA: Body Surface Area

39 CRO: contract research organization

DLQI: Dermatology Life Quality Index

IMQ: imiquimod

ITT: Intent-to-treat

IWRS-CMT: Interactive Web Response System for Chinese Medicine Trials

KUMCR: Key Unit of Methodology in Clinical Research

PASI: Psoriasis Area and Severity Index

SAS: Self-rating Anxiety Scale

SDS: Self-rating Depression Scale

TCM: Traditional Chinese Medicine

VAS: Visual analogue scale

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

Jingwen Deng, Danni Yao and Chuanjian Lu drafted the manuscript. Chuanjian Lu and Zehuai Wen participated in the design of the study, Danni Yao, Yuhong Yan, Ziyang He, Huimei Wu and Hao Deng coordinate the study. All authors participated in, read, and approved the final manuscript.

Acknowledgments

This research was supported by grants of the National Key Technology R&D Program for the 12th Five-year Plan of Ministry of Science and Technology, China (No. 2013BAI02B03), Provincial Science and Technology Project of Guangdong Province, China (No.2015B020211013) and Guangdong Provincial Bureau of traditional Chinese Medicine Research Project (No.20161110).

We thank Prof. Guo-Wei Xuan (Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China), Profs. Ai-E Xu and Jun-Jun Shan (The Third Hospital of Hangzhou, Hangzhou, China), Profs. Jun-ling Zhang and Hong-mei Wang (Affiliated Hospital of Tianjin Chinese Medicine Academy) for their suggestions. We also thank Mr Wen-Wei Ouyang and Dr Li-Ming Lu (Guangdong Provincial Hospital of Chinese Medicine) for comments and suggestions on data management and the statistical analysis plan.

References

1. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2009. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2009.
2. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annu Rev Pathol.* 2012;7:385–422.
3. Ben Salem C, Hmouda H, Bouraoui K. Psoriasis. *The New England journal of medicine.* 2009 Oct 22;361(17):1710
4. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. *Molecular immunology.* 2015 Apr;64(2):313-23.
5. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *The Journal of investigative dermatology.* 2013 Feb;133(2):377-85.
6. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet.* 2007 Jul 21;370(9583):263-71.
7. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). *Archives of dermatological research.* 2012 Mar;304(2):87-113.
8. Zhang CS, Yang L, Zhang AL, May BH, Yu JJ, Guo X. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. *J Altern Complement Med.* 2016 Mar;22(3):174-88.
9. May BH, Zhang AL, Zhou W, Lu CJ, Deng S, Xue CC. Oral herbal medicines for psoriasis: a review of clinical studies. *Chin J Integr Med.* 2012;18:172-8.
10. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, et al. Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. *Int J Dermatol.* 2014;53(11):1305–18.
11. Deng S, May BH, Zhang AL, Lu C, Xue CC. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. *Br J Dermatol.* 2013 Oct;169(4):769-82.
12. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal formulae in the management of psoriasis: systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs. *Phytother Res.* 2014 Apr;28(4):480-97.
13. Yang L, Zhang CS, May B, Yu J, Guo X, Zhang AL, et al. Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis. *Chin Med.* 2015 Sep 26;10:27.
14. Deng S, May BH, Zhang AL, Lu C, Xue CC. Phytotherapy in the management of

1
2
3 psoriasis: a review of the efficacy and safety of oral interventions and the
4 pharmacological actions of the main plants. *Arch Dermatol Res.* 2014
5 Apr;306(3):211-29.

6
7
8 15. Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C. Add-on effect of chinese
9 herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review. *Evid*
10 *Based Complement Alternat Med.* 2013;2013:673078.

11
12 16. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal medicine combined
13 with pharmacotherapy for psoriasis: a systematic review and meta-analysis. *Arch*
14 *Dermatol Res.* 2013 Apr;305(3):179-89.

15
16
17 17. Lu CJ, Yu JJ, Deng JW. Disease-syndrome combination clinical study of
18 psoriasis: present status, advantages, and prospects. *Chin J Integr Med.* 2012
19 Mar;18(3):166-71.

20
21 18. Han L, Peng Y, Zhao RZ, Feng B, Lu CJ. Effect of Yinxieling on proliferation of
22 HaCaT. *J Guangzhou Univ TCM* 2011; 28(2): 159-162.

23
24 19. Lu CZ, Wu XX, Liu FN. Effect of Yinxieling on PCNA expression and apoptosis
25 of keratinocyte. *Trad Chin Drug Res Clin Pharmacol* 2006; 17(5): 329-331.

26
27 20. Lei Wang, Yongjing, Huang, Minghua Wang. Clinical Observation of Yinxieling
28 Tablets for the Treatment of Psoriasis Vulgaris. *Journal of Guangzhou University of*
29 *Traditional Chinese Medicine.* 2009 Nov; 26(6): 520-5.

30
31 21. Dai YJ, Li YY, Zeng HM, Liang XA, Xie ZJ, Zheng ZA. Effect of Yinxieling
32 decoction on PASI, TNF- α and IL-8 in patients with psoriasis vulgaris. *Asian Pac J*
33 *Trop Med.* 2014 Aug;7(8):668-70.

34
35 22. Yan YH, Zhao RZ, Lu CJ. Optimization of Yinxieling Capsule with orthogonal
36 design. *Lishizhen Medicine and Materia Medica Research.* 2014; 25(11): 2763-5.

37
38 23. Wei Zhu, He Songmin, Yuan Xiaohong, Lu Chuanjian. Computerized Systematic
39 Pharmacological Research of Yinxieling Formula. *Traditional Chinese Drug Research*
40 *and Clinical Pharmacology.* 2011; 22(4): 379-82.

41
42 24. Yan YH, Lu CJ. Effect of modified Yinxieling on pustular psoriasis. *Trad Chin*
43 *Drug Res Clin Pharmacol* 2011; 22(6): 691-3.

44
45 25. Lu C, Deng J, Li L, Wang D, Li G. Application of metabolomics on diagnosis and
46 treatment of patients with psoriasis in traditional Chinese medicine. *Biochim Biophys*
47 *Acta.* 2014 Jan;1844(1 Pt B):280-8.

48
49 26. J.A. Wei, L. Han, C.J. Lu, et al., Formula PSORI-CM01 eliminates psoriasis by
50 inhibiting the expression of keratinocyte cyclin B2, *BMC Complement. Altern. Med.*
51 16 (1) (2016 Jul 29) 255.

- 1
2
3 27. Han L, Sun J, Lu CJ, Zhao RZ, Lu Y, Lin HJ, et al. Formula PSORI-CM01
4 inhibits the inflammatory cytokine and chemokine release in keratinocytes via NF- κ B
5 expression. *Int Immunopharmacol*. 2017 Mar;44:226-233.
6
7
8 28. Psoriasis Group of Dermatology and Venereology: Chinese Medical Association.
9 Clinical guidelines of psoriasis 2008. *Chin J Dermatol (Chin)*. 2009;42, 213-4.
10
11 29. Yao DN, Lu CJ, Wen ZH, Yan YH, Xuan ML, Li XY, Li G, et al. Oral
12 PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for
13 moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized,
14 placebo-controlled trial. *Trials*. 2016 Mar 16;17(1):140.
15
16
17 30. Sedgwick P: What is intention to treat analysis? *BMJ* 2013, 346: f3662–f3662.
18
19 31. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial
20 burden of psoriasis. *American journal of clinical dermatology*. 2005;6(6):383-92.
21
22 32. Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of
23 developing psychiatric disorders in pediatric patients with psoriasis. *Journal of the*
24 *American Academy of Dermatology*. 2012 Oct;67(4):651-7.
25
26 33. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. *The*
27 *Australasian journal of dermatology*. 2004 Aug;45(3):155-9.
28
29 34. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive
30 sleep apnea: a longitudinal population-based study. *Sleep medicine*. 2012
31 Mar;13(3):285-9.
32
33 35. Farley E, Menter A. Psoriasis: comorbidities and associations. *Giornale italiano di*
34 *dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e*
35 *sifilografia*. 2011 Feb;146(1):9-15.
36
37 36. Slobodin G, Rosner I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic
38 arthropathy: where now? *The Israel Medical Association journal : IMAJ*. 2009
39 Jul;11(7):430-4.
40
41 37. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM.
42 Cause-specific mortality in patients with severe psoriasis: a population-based cohort
43 study in the U.K. *The British journal of dermatology*. 2010 Sep;163(3):586-92.
44
45 38. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and
46 Metabolic Syndrome--scientific evidence and therapeutic implications. *Journal of*
47 *medicine and life*. 2014 Oct-Dec;7(4):468-71.
48
49 39. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al.
50 Evaluating the economic burden of psoriasis in the United States. *Journal of the*
51 *American Academy of Dermatology*. 2015 Apr 14.
52
53
54
55
56
57
58
59

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
40. Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, et al. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. *J Invest Dermatol*. 2015 Dec;135(12):2955-63.
41. Wen ZH, Xuan ML, Yan YH, Li XY, Yao DN, Li G. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. *Trials*. 2014 Jul 22;15:294.
42. Parker S, Zhang AL, Zhang CS, Goodman G, Wen Z, Lu C. Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial. *Trials*. 2014 Dec 19;15:495.
43. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT: Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med* 2013, 2013:200–207.
44. Moher D, Schulz KF, Altman DG: CONSORT. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. *BMC Med Res Methodol* 2001, 1:2.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of the study.

297x420mm (300 x 300 DPI)



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	7, Table.1
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	7-8
	7b	When applicable, explanation of any interim analyses and stopping guidelines	9
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9

1				
2				
3				
4		11b	If relevant, description of the similarity of interventions	
5	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9
6		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	9
7				
8	Results			
9	Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	9
10	diagram is strongly		were analysed for the primary outcome	
11	recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	
12	Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
13		14b	Why the trial ended or was stopped	
14				
15	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
16	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was	
17			by original assigned groups	
18				
19	Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	
20	estimation		precision (such as 95% confidence interval)	
21		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
22	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
23			pre-specified from exploratory	
24				
25	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
26				
27	Discussion			
28	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
29	Generalisability	21	Generalisability (external validity, applicability) of the trial findings	
30	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
31				
32	Other information			
33	Registration	23	Registration number and name of trial registry	1
34	Protocol	24	Where the full trial protocol can be accessed, if available	
35	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	12
36				

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	15
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	1, 6,15

Introduction

5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5
8		6b	Explanation for choice of comparators	5
10	Objectives	7	Specific objectives or hypotheses	5
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
16	Methods: Participants, interventions, and outcomes			
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6,7
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6,8
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	12
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, Table 1
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6-8, Figure 1

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
7				
8	Methods: Assignment of interventions (for controlled trials)			
9				
10	Allocation:			
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10,11
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10,11
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	10,11
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	10,11
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
29				
30				
31				

32 **Methods: Data collection, management, and analysis**

33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11,12
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11,12
40				
41				
42				
43				
44				
45				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11
13				
14				
15				
16	Methods: Monitoring			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	12
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11,12
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
30				
31				
32				
33	Ethics and dissemination			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	1, 6
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	6
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	6
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	NA
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	1
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	15
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
36				
37				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol for a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014475.R2
Article Type:	Protocol
Date Submitted by the Author:	12-Jul-2017
Complete List of Authors:	Deng, Jingwen; Dermatology Yao, Danni; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Lu, Chuan-jian ; Guangdong Provincial Hospital of Traditional Chinese Medicine, Department of dermatology Wen, Zehuai; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Yan, YuHong; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology He, Ziyang; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Wu, Huimei; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Deng, Hao; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, Chinese Herbal Medicine, Clinical Trial, Protocol

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol for a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Jingwen Deng^{1,2,†}, Danni Yao^{1,2,†}, Chuanjian Lu^{1,2,3*}, Zehuai Wen⁴,
Yuhong Yan^{1,2}, Ziyang He¹, Huimei Wu^{1,2}, Hao Deng^{1,2}

Abstract

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Introduction: Psoriasis vulgaris (PV) is a common skin disease that is characterized by persistent localized erythematous scaly plaques. Yinxieling is a Chinese herbal formula for psoriasis that has been used for more than 20 years in China. To facilitate application, PSORI-CM01 was developed based on the optimization and simplification of Yinxieling tablets performed in a previous study and in clinical practice. However, the scientific evidence regarding whether PSORI-CM01 is more effective for psoriasis than the original Yinxieling remains insufficient. Therefore, we designed a randomized clinical trial to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granules compared with those of Yinxieling tablets for the treatment of patients with psoriasis.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Methods and analysis: This on-going study is a two-arm parallel, randomized, double-blind, double-dummy clinical trial. Five hundred fifty-six participants with psoriasis will be recruited and then randomly allocated into two groups in a 1:1 ratio. Participants in PSORI-CM01 group will receive a 5.5-g granule of PSORI-CM01 twice daily and five placebo tablets three times daily for 12 weeks. The participants in the Yinxieling group will receive five Yinxieling tablets three times daily and a placebo granule twice daily for 12 weeks. The primary outcome is the reduction of the Psoriasis Area and Severity Index (PASI). The secondary outcomes include relapse rate, visual analogue scale (VAS) scores, body surface area (BSA), and the Dermatology Life Quality Index (DLQI). Cost effectiveness analysis will be performed from a health and community care provider perspective.

47
48
49
50
51
52
53
54
55

Ethics and dissemination: This research protocol had been reviewed and approved by the institutional review boards of three trial centres (Guangdong Provincial Hospital of Chinese Medicine (B2014-026-01), Affiliated Hospital of Tianjin Chinese Medicine Academy (2014-KY-001) and Third Hospital of Hangzhou (B2014-026-01)). The findings will be disseminated to the public through conference presentations and open access journals.

56
57

Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-14005185

58
59

[†]Jingwen Deng and Danni Yao contributed equally to this work.

60
1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*** Correspondence:**

Chuanjian Lu

luchuanjian888@vip.sina.com

Strengths and limitations of this study

- We are performing a trial to provide evidence regarding the clinical effectiveness of a Chinese medicine treatment for psoriasis before and after optimization and simplification. There is no absolute placebo control, which means that this trial will be unable to assess the absolute efficacy and will assess only the relative efficacy.
- Participants will be randomized to either a PSORI-CM01 granule with Yinxieling placebo tablet group or a Yinxieling tablet with PSORI-CM01 placebo granule group. The primary outcome is the reduction of the PASI score at week 12.
- For broad use of the herbal formula, we designed PSORI-CM01 based on the rule “treated from the blood”, which is related to the core pathogenesis of psoriasis in Traditional Chinese Medicine (TCM) theory. This formula can be applied to the blood heat, blood stasis, and blood dryness syndromes of psoriasis. Therefore, there is no stratification based on TCM syndromes in the design of the trial.

Authors' information

1. Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China;
2. Psoriasis clinical and basic research team, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou 510120, China;
3. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 510120, China
4. Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Authors' contact information

JingWen Deng, e-mail: s6891@163.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

DanNi Yao, e-mail: yaodanni1984@163.com,

Tel:+8620-81887233-30603, Fax:+8620-81874903

ChuanJian Lu, e-mail: luchuanjian888@vip.sina.com

Tel:+8620-81887233-31223, Fax:+8620-81874903

ZeHuai Wen, e-mail: wenzh@gzucm.edu.cn,

2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tel:+8620-81887233-31227, Fax:+8620-81874903

YuHong Yan, e-mail: yanyuhong7966@139.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

ZiYang He, e-mail: ziyanghe@qq.com,

Tel:+8620-81887233-31227, Fax:+8620-81874903

HuiMei Wu, e-mail: 691892927@qq.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

Hao Deng, e-mail: 563435624@qq.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

For peer review only

Background:

Psoriasis is a chronic, immune-mediated, inflammatory skin disease characterized by erythema, scale and redness, and thickening and scaling of the skin. The main histopathologic change of psoriasis is accelerated keratinocyte cell proliferation^{1, 2}. However, the cause of this disease remains unknown. Although an early concept of the pathogenesis of psoriasis focused on the proliferation and differentiation of keratinocytes, recent studies have recognized that dysregulation of the immune system plays a critical role in the development of psoriasis. The interactions between dendritic cells, T cells, keratinocytes, neutrophils, and the cytokines released from immune cells are the core mechanism of the development of psoriasis³. Genetic, environmental and behavioural factors are thought to be triggers that contribute to the onset of psoriasis⁴. The prevalence of psoriasis in adults is estimated to range from 0.91% to 8.5% worldwide⁵. Clinically, psoriasis vulgaris is the most common subtype of psoriasis and affects approximately 90% of patients⁶.

The most common treatments for psoriasis include topical medication, ultraviolet light, systematic drugs and biologics. Topical medications, such as corticosteroids, retinoid and vitamin D analogues, are considered to be first-line therapies for psoriasis vulgaris. Systematic drugs are for severe psoriasis, while ultraviolet light and biologics are used when applicable and necessary⁷.

A series of systematic reviews have demonstrated that Chinese Medicine contains an effective therapy for psoriasis⁸⁻¹⁶. Yinxieling tablets, which are a Chinese herbal medicine compound preparation with 10 ingredients (i.e., *angelica sinensis*, *radix paeoniae rubra*, *chloanthus spicatus*, *smoked plum*, *radix rehmanniae recen*, *ligusticum wallichii*, *radices lithospermi*, *curcuma zedoary*, and *rhizome smilacis glabrae*, *liquorice*) that is used for the treatment of psoriasis, was developed by the National Medical Master Guo-wei Xuan, who is a well-known Chinese medicine doctor. These tablets were formulated according to traditional Chinese medicine theory and are theoretically effective and safe. In TCM theory, three syndromes of psoriasis are generally acknowledged: blood stasis, blood heat, and blood dryness type. In the acute stage, the pathogenesis of psoriasis vulgaris is mostly blood heat that is obstructed on the surface of the skin. In the chronic stage, the pathogenesis of psoriasis vulgaris is blood deficiency that develops into dryness that prohibits the nourishing of the skin or blood stasis that obstructs blood flow in skin collaterals. Therefore, activating blood circulation and removing blood stasis should be the focus of curing of psoriasis. Yinxieling tablets play the role of activating blood circulation and removing blood stasis in the treatment of psoriasis¹⁷.

In the recent 20 years of clinical practice, Yinxieling tablets have been extensively used for the treatment of psoriasis and have exhibited a promising clinical efficacy in terms of relieving the symptoms of psoriasis and reducing the relapsing rate. Molecular biological technologies have been used to analyse the pharmacological

1
2
3 mechanisms of multiple ingredients in Yinxieling tablets^{18, 19}. These studies have
4 demonstrated that Yinxieling tablets are involved in the regulation of
5 immune-mediated cells and the interaction of cellular cytokines, which has revealed
6 the potential mechanism of Yinxieling tablets in the treatment of psoriasis. In the
7 exploration of the molecular and pharmacological mechanisms of Yinxieling tablets,
8 two clinical trials have been performed to confirm their clinical effectiveness. In
9 Wang's study, 24 patients with psoriasis were equally randomized into the following
10 two groups: a treatment group that received Yinxieling tablets for eight weeks and a
11 control group that received acitretin capsules for eight weeks. The therapeutic effect
12 of the Yinxieling tablets in the treatment of psoriasis was similar to that of the
13 acitretin capsules, but fewer side effects appeared in the Yinxieling tablet group²⁰. In
14 Dai's study, 90 patients in observation groups were treated with Yinxieling, and
15 30 patients in a control group were treated with placebo for 8 weeks. The result
16 revealed that the Yinxieling decoction had a therapeutic effect on psoriasis vulgaris²¹.
17 However, there are limitations to the further development of Yinxieling because of its
18 complex compounds.

19 To expand the application of Yinxieling, an optimized formula, i.e., PSORI-CM01
20 (former name YXBCM01), was developed. This formula is composed of only seven
21 ingredients (i.e., *radix paeoniae rubra*, *smoked plum*, *chloranthus spicatus*, *radices*
22 *lithospermi*, *curcuma zedoary*, *rhizome smilacis glabrae*, and *liquorice*) of the
23 Yinxieling tablet that were found to have positive correlations with pharmacodynamic
24 indicators based on a computerized systematic pharmacological method and
25 orthogonal experiments^{22, 23}. An observational study revealed that two months of
26 treatment with PSORI-CM01 for psoriasis vulgaris reduced the PASI and DLQI
27 scores with no adverse events²⁴. Another 12-week observational study revealed that
28 the PASIs of patients with psoriasis were reduced after PSORI-CM01 treatment, and
29 the metabolic variations were observed in patients with psoriasis before and after
30 PSORI-CM01 treatment²⁵. Our previous study demonstrated that PSORI-CM01 can
31 reduce keratinocyte proliferation in vitro and inhibit epidermal hyperplasia in an
32 imiquimod (IMQ)-induced psoriasis-form mouse model²⁶. The PSORI-CM01 formula
33 can also affect the IL-17/IL-23 axis and inhibit the expression of cytokines and
34 chemokines and thus improve inflammatory conditions in the dermic
35 microenvironment²⁷.

36 However, the previous studies of PSORI-CM01 are all based on preliminary clinical
37 observations and animal experiments. Whether the clinical efficacy and safety of
38 PSORI-CM01 granules are better than those of its prototype, i.e., the Yinxieling tablet,
39 remains uncertain. Therefore, a rigorously designed randomized controlled trial to
40 determine whether PSORI-CM01 is more effective than the Yinxieling tablet and to
41 investigate the efficacy and safety of this new formula is warranted.

42 Method

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Design

This is a double-dummy, double-blind, randomized, controlled trial to investigate the efficacy and safety of the new formula PSORI-CM01 granule compared with its prototype, the Yinxieling tablet. This study will be performed in three centres in China: the Guangdong Provincial Hospital of Chinese Medicine, the Affiliated Hospital of Tianjin Chinese Medicine Academy, and the Third Hospital of Hangzhou. Because Yinxieling tablets and PSORI-CM01 granules have different preparation forms, a double-dummy, double-blind trial design was selected to guarantee rigorous blinding. The study procedure consists of three components, i.e., an initial screening, a treatment period, and a follow-up period. In the initial screening, patients with psoriasis will be recruited via a dermatology clinic for physical examination and inclusion assessment. A two-week run-in period may be requested depending on the results of the assessments. If eligible, written informed consent will be requested of the participants. Additional consent provisions for collection and use of participant data and biological specimens will be requested as well. All details of the informed consent will be clearly explained to the participant to assure their understanding. Once informed consent is obtained, a participant will be given a random sequence number. All participants will be allocated into two groups at a ratio of 1:1. One group will receive PSORI-CM01 granules with Yinxieling placebo tablets, and the other group will receive Yinxieling tablets with PSORI-CM01 placebo granules (Fig. 1). We will collect patients' information about TCM syndromes before and after the treatment. Target lesions will be recorded with digital photographs taken with SLR cameras at every visit.

The trial protocol was approved by the Guangdong Provincial Hospital of Chinese Medicine ethics committee, and registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-14005185).

Eligibility criteria

Inclusion criteria

The patients must meet all of the following criteria at the time of randomization to be eligible for recruitment:

- (1) The patients must meet the criteria for the diagnosis of psoriasis vulgaris referred to in the Clinical Guidelines of Psoriasis 2008 reported by the Chinese Medical Association²⁸.
- (2) Male and female patients must be between 18 and 65 years old.
- (3) A PASI of more than 3 and less than 30, and a BSA of less than 30% are required.
- (4) Informed consent must be obtained.

Exclusion criteria

The trial exclusion criteria include any of the following:

- (1) Psoriatic lesions can only be seen on the face, scalp, nails, anus, mucus and

1
2
3 palmar-plantar areas.

4 (2) Acute progressive psoriasis, an erythroderma tendency, and psoriatic arthritis are
5 present.

6
7 (3) Patients who are pregnant, lactating, and those who plan to become pregnant
8 within a year will be excluded.

9
10 (4) Those with an SAS more than 50 or an SDS more than 53, and those with other
11 psychiatric disorders will be excluded.

12
13 (5) Those with a history of primary cardiovascular, respiratory, digestive, urinary,
14 endocrinologic and haematologic diseases that cannot be controlled with ordinary
15 treatments will be excluded. Those with malignant diseases, infections, electrolyte
16 imbalances, and acid-base disturbances will be excluded. Patients with the following
17 clinical test results will be excluded: an AST or ALT 3 times greater than the normal
18 upper limit, creatinine 1.5 times greater than the normal upper limit; haemoglobin
19 elevated by 20 g/L above the normal upper limit; a platelet count less than $75.0 \times 10^9/L$;
20 a white blood cell count less than $3.0 \times 10^9/L$, and other abnormal laboratory test
21 results, as assessed by the investigators, which are not suitable for this clinical study.

22
23 (6) Patients who are allergic to any medicine or ingredients used in this study will be
24 excluded.

25
26 (7) Those participating other clinical trials and those who have participated in trials
27 within 1 month will be excluded.

28
29 (8) Patients who have used corticosteroids or retinoic acid acting on the skin over the
30 previous 2 weeks, those on systemic therapy or phototherapy (UVB and PUVA) with
31 the previous 4 weeks, and those on biological therapy over the previous 12 weeks will
32 be excluded.
33
34
35
36
37

38 **Interventions**

39 **PSORI-CM01 group**

40 Participants in PSORI-CM01 group will receive 5.5 PSORI-CM01 granules twice
41 daily after meals and five placebo tablets three times daily after meals for 12 weeks.

42 **Yinxieling group**

43 Participants in Yinxieling group will receive five Yinxieling tablets three times daily
44 after meals and placebo granules 5.5 g twice daily after meals for 12 weeks.
45
46
47
48

49 **Outcome measures**

50 **Primary outcome**

51 The primary outcome is the reduction in the PASI score, which will be calculated as
52 follows:
53

54 Reduction of the PASI = PASI at baseline - PASI at week 12.

55 The PASI scores of the patients will be assessed every 2 weeks during the treatment
56
57
58
59
60

1
2
3 period and every 4 weeks during the follow-up period. The PASI reduction calculated
4 at week 12 will be considered the primary outcome.
5

6 7 **Secondary outcomes**

8 The secondary outcome measures include relapse rate, BSA, VAS and DLQI. The
9 VAS and BSA will be assessed every 2 weeks during the treatment period and every 4
10 weeks in the follow-up period. The DLQI will be assessed by the patients every 4
11 weeks during the treatment period. In the follow-up period, the DLQI will only be
12 assessed at the last week (the 24th week). Laboratory reports were also be monitored
13 until the last visit (Table. 1).
14

15 16 17 **Health economics**

18 An economic evaluation will be performed from the perspective of the Health
19 Department of Guangdong Province and will occur in the form of cost-utility analysis
20 and will be conducted using utility values obtained from the DLQI preference-based
21 quality of life measure. The DLQI is a dermatology-specific quality of life instrument
22 for routine clinical use. This instrument is a validated questionnaire with a simple
23 10-question format. At present, the DLQI is the most frequently used instrument for
24 evaluating the effects of skin disease and related treatments on patients' lives. The
25 DLQI will be measured at baseline and at 4 and 16 weeks for utility-based quality of
26 life evaluation in this study. Resource use will include intervention costs, healthcare
27 costs and community service costs, which will be calculated for each trial participant.
28 We will analyse an incremental cost-effectiveness ratio (ICER) of the cost per patient
29 by calculating the incremental mean difference in costs between the two trial arms and
30 the incremental difference in patient outcome after the follow-up.
31
32

33 34 35 36 37 38 39 40 41 **Sample size**

42 Due to the lack of studies evaluating the effects of PSORI-CM01 granule and
43 Yinxieling tablets on psoriasis that are available for sample size calculation, we
44 performed the sample calculation based on our previous study's results and experts'
45 opinions²⁹. The superiority-test for two means was used for the sample size
46 calculation. We assumed that the superiority margin of the PASI was 1.5, and the
47 standard deviations were 1.1 and 2.5 for the PSORI-CM01 granules and Yinxieling
48 tablets, respectively. The significance level (alpha) of the test was 0.025, and
49 statistical power was 80%. A sample size of 236 was deemed necessary for the each
50 arm after the calculations. Considering a 15% loss to follow-up, 278 patients are
51 needed in each arm for a total of 556 patients. The PASW Statistics software (version
52 18.0; IBM Inc., Chicago, IL, USA) was used for the calculations.
53
54
55
56
57
58
59
60

8

Table 1 Schedule for treatment and outcome measurements

Period	Time points	Enrolment	Allocation	Treatment period						Follow-up period			
		-1w	0w	2w	4w	6w	8w	10w	12w	16w	20w	24w	
Enrolment	Eligibility screening	●											
	Informed consent	●											
	Characteristic	●											
	Medical history	●											
	Laboratory examination		●						●				
	Biological specimens		●						●				
	Random allocation		●										
	Intervention	PSORI-CM01 granules and placebo tablets		☆	—————						☆		
Yinxieling tablets and placebo granules			★	—————						★			
Assessment	TCM syndrome		●						●			●	
	PASI	●	●	●	●	●	●	●	●	●	●	●	
	BSA	●	●	●	●	●	●	●	●	●	●	●	
	VAS	●	●	●	●	●	●	●	●	●	●	●	
	DLQI		●						●			●	
	SAS	●											
	SDS	●											
	Safety assessment	●	●	●	●	●	●	●	●	●	●	●	

☆: For PSORI-CM01 group

★: For Yinxieling group

Randomisation and allocation

Eligible patients will be randomly assigned, in a 1:1 ratio, to one of the two treatment groups (PSORI-CM01 group or Yinxieling group) at the second visit through central randomization. Equal randomization will be conducted using a computer-generated random allocation sequence through the stratified block randomization method of the SAS software (version 9.12; SAS Institute, Inc., Cary, NC, USA) by the Key Unit of Methodology in Clinical Research (KUMCR) of Guangdong Provincial Hospital of Chinese Medicine. Allocation concealment will be ensured, as the randomization code will be released by the Interactive Web Response System for Chinese Medicine Trials (IWRS-CMT), which was a verified online randomization facility established by the KUMCR (<http://www.gztcmgcp.net/sjxt/login.asp>). After that, the participants will be randomly allocated to two different treating groups.

Test drugs and blinding

After preliminary clinical observations, we changed the form of the PSORI-CM01 formula to granules because the preparation of oral granules normally involves smooth, quick water absorption and swelling properties that allow for easy swallowing.

The PSORI-CM01 granules and the matching placebo granules used in the trial were prepared by Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, Jiangsu Province, China). The Yinxieling tablets and the matching placebo tablets were prepared by Kangyuan Pharmaceutical Co., Ltd. (Guangzhou, Guangdong Province, China). All of the above drugs met the requirements of Good Manufacturing Practice (GMP). The main ingredients of the placebo granules and the placebo tablets are maltodextrin, lactose, and a natural edible pigment, and these ingredients are similar to those of the PSORI-CM01 granules and Yinxieling tablets in appearance, weight, and taste.

The practitioners will be blind to the allocation arm, and the arms will have similar medical procedures. Moreover, the evaluations of the participants and the analysis of the results will be performed by physician assessors and statisticians who are blinded to the group allocation.

Statistical analysis

All analyses will be performed with PASW Statistics and SAS 9.2 software by a statistician who is blinded to the random allocation of groups. Intent-to-treat (ITT)-based statistical analyses with 95% confidence intervals will be performed. The

10

1
2
3 ITT analyses will include all of the patients who are randomized³⁰. Safety analysis
4 will be undertaken by analysing the frequency of adverse events that are suspected to
5 be related to the treatment. The various parameters observed will be compared using
6 the chi-square test for non-continuous variables (i.e., the primary outcome and relapse
7 rate), and t-tests and analyses of variance (ANOVAs) will be used for the continuous
8 variables. Rank or skewed (not follow normality) data in these analyses will be
9 examined using Wilcoxon signed-rank test. To distinguish the treatment effect and the
10 time effect, repeated measures analysis of variance of the change from baseline will
11 be performed for the different time point assessments. A subgroup analyses will be
12 performed based on the severity of the disease and the TCM syndromes. Statistical
13 significance will be established at $P < 0.05$.

21 22 **Adverse events**

23 Before the beginning of, and after 12 weeks of treatment, medical histories will be
24 recorded for each patient, and standard laboratory examinations and specific
25 laboratory investigations will also be performed. The standard laboratory
26 examinations will include the following: haematologic parameter assessment
27 (haemoglobin, and red blood cell, platelet, and white blood cell counts); urinalysis
28 (proteins, and red and white blood cell biochemical assessments (serum electrolytes),
29 indices of renal function (creatinine and urea) and hepatic function (alkaline
30 phosphatase, aspartate amino transferase, alanine amino transferase, and
31 g-glutamyl-transpeptidase); and electrocardiograms. The specific laboratory
32 investigations mainly include the serum cytokine levels.

33 All adverse events will be collected and graded for severity and potential relation to
34 the treatments by assessors at every visit. The safety evaluations include the incidence
35 of treatment-induced or serious adverse events, dropout due to adverse events, and
36 laboratory parameter changes. In cases of severe adverse effects, all drugs in this trial
37 will be immediately discontinued.

48 49 **Data management**

50 All physicians, assessors and research assistants will attend training workshops before
51 the conduction of trial. Investigators in different centre will all be required to follow
52 the standard operating procedures. The quality controllers from the contract research
53 organization (CRO) Guangdong International Clinical Research Center of Chinese
54 Medicine (Guangzhou, China) will perform regular monitoring in each centre

1
2
3 throughout the trial. All study data will be managed as detailed in the full trial
4 protocol and in accordance with the data management plan, which was developed by
5 the Data Monitoring Committee of the Guangdong Provincial Hospital of Chinese
6 Medicine (GPHCM). The data collection will include all information in the case
7 report forms. The data will be entered using the double entry method. To ensure
8 data quality and data consistency between the source data and the data entered into
9 the database, two research assistants will independently input the data from the CRFs
10 into database using a prespecified database software that was developed by the Data
11 Monitoring Committee. The Data Monitoring Committee will assess the safety data
12 and the critical efficacy outcomes after the trial is finished.
13
14
15
16
17
18
19
20
21

22 Discussion

23
24 Psoriasis is a disease of immune abnormality that progresses slowly over a long
25 period with frequent symptom recurrences. Psoriasis causes detrimental effects on
26 the quality of life of both adults and children. Elevated rates of various
27 psychopathologies, including poor self-esteem, sexual dysfunction, anxiety,
28 depression, and suicidal ideation, have been reported in patients with psoriasis³¹⁻³⁵.
29 Psoriasis is not a disease that only affects the skin. Increasing evidence supports the
30 recognition of psoriasis as a chronic multisystem inflammation disorder with
31 multiple associated comorbid conditions. Comorbidities linked to psoriasis include
32 psoriatic arthritis, cardiovascular diseases, obesity, metabolic syndrome, malignancy,
33 hypertension, and inflammatory bowel disease²⁵. Psoriatic arthritis (PsA) is an
34 erosive and deforming joint disease that is associated with psoriasis and affects 7%
35 to 42% of the psoriasis population³⁶. PsA-induced joint damaging complications not
36 only lead to lower articular function and higher mortality but also affect patients'
37 abilities to work and their social relationships³⁷. In patients with severe psoriasis, the
38 life expectancy is reduced by 5 years primarily due to cardiovascular disease³⁷.
39 Additionally, psoriasis has a strong connection with metabolic syndrome, which
40 makes it a marker for increased risks of the morbidities and mortalities associated
41 with these diseases³⁸. Psoriasis can also cause substantial economic loss. According
42 to a systematic literature review conducted by the American Academy of
43 Dermatology, the total direct and indirect burden of psoriasis is estimated to be \$35.2
44 billion in the U.S. per annum³⁹.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The treatments used for moderate to severe psoriasis (i.e., phototherapy and oral
4 systemic and biologic therapies) were received by 27.3% of the total psoriasis
5 sample, of whom 37.2% used biologics⁴⁰. Orally
6 administered Chinese herbal medicine has been used for the clinical management
7 of psoriasis for years. However, a number of high-quality clinical trials are needed
8 before Chinese herbal medicine can be recommended for psoriasis. We conducted a
9 series of systematic reviews to evaluate the effects of Chinese herbal medicine alone
10 and in combination with pharmacotherapy for psoriasis⁸⁻¹⁶. The results revealed that
11 there is promising evidence of positive effects from a number of studies of
12 multi-herb formulations.
13
14

15
16
17
18
19 We changed the form of the PSORI-CM01 formula to granules in this study.
20 Considering too many blood-activating and stasis-dissolving drugs would cause
21 consumption of Qi, we removed *angelica sinensis*, *radix rehmanniae recen*,
22 *ligusticum wallichii* from Yinxieling. The remain seven herbs turned to be
23 PSORI-CM01. Tablets containing micronized Chinese herbal medicine are not
24 suitable for immediate release. Granules are solid when stored and will swell and gel
25 via water absorption. Additionally, granules from simplified formulations offer great
26 opportunities to improve continuous processes, present performances comparable to
27 more complicated formulations and are able to correspond to the requirements of the
28 authorities. In this study, the micro-structure and tensile strength of the granules
29 resembled those of the tablets formed from the original ungranulated powder.
30
31

32 To our knowledge, this trial is the first study to compare the clinical effectiveness of
33 Chinese medicine treatment for psoriasis before and after optimization and
34 simplification. Moreover, we aim to provide supporting data for the effectiveness of
35 the PSORI-CM01 granule that resulted from the optimization of Yinxieling tablet as
36 determined in a previous study and clinical practice. This study is the third clinical
37 trial that our research team has conducted on the effectiveness of the PSORI-CM01
38 granule for patients with psoriasis. The first study compared oral the PSORI-CM01
39 granule plus topical sequential therapy for moderate to severe psoriasis and was a
40 double-blind, randomized placebo-controlled trial that evaluated the effectiveness of
41 PSORI-CM01 combined with usual topical therapy compared with the usual topical
42 therapy that is used in the clinical practice of Western medicine alone^{29, 41}. The second
43 study evaluated oral PSORI-CM01 granule plus topical calcipotriol for psoriasis
44 relative to placebo plus topical calcipotriol over 12 weeks; this study was a pilot
45 randomized, placebo-controlled, double-blinded trial⁴². These two trials aimed to
46 evaluate the benefits of the addition of PSORI-CM01 granules compared with
47 conventional treatments of psoriasis. In contrast to the above two trials, the present
48 clinical trial protocol acts as the foundation for evaluating the treatment of psoriasis
49
50
51
52
53
54
55
56
57
58
59
60

with Chinese medicine.

For facilitating appropriate reference standards for scientific, ethical and safety issues before the trial begins, this protocol has been developed according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 and Consolidated Standards of Reporting Trials (CONSORT) statement^{43, 44}.

Trial status

The recruitment phase began in November 2014. Thus far, 63 patients have been recruited. The estimated end date for this study is in October 2018.

Abbreviations

ANOVA: Analysis of variance

BSA: Body Surface Area

CRO: contract research organization

DLQI: Dermatology Life Quality Index

IMQ: imiquimod

ITT: Intent-to-treat

IWRS-CMT: Interactive Web Response System for Chinese Medicine Trials

KUMCR: Key Unit of Methodology in Clinical Research

PASI: Psoriasis Area and Severity Index

SAS: Self-rating Anxiety Scale

SDS: Self-rating Depression Scale

TCM: Traditional Chinese Medicine

VAS: Visual analogue scale

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

Jingwen Deng, Danni Yao and Chuanjian Lu drafted the manuscript. Chuanjian Lu and Zehuai Wen participated in the design of the study, Danni Yao, Yuhong Yan, Ziyang He, Huimei Wu and Hao Deng coordinate the study. All authors participated in, read, and approved the final manuscript.

Acknowledgments

This research was supported by grants of the National Key Technology R&D Program

1
2
3 for the 12th Five-year Plan of Ministry of Science and Technology, China (No.
4 2013BAI02B03), Provincial Science and Technology Project of Guangdong Province,
5 China (No.2015B020211013) and Guangdong Provincial Bureau of traditional
6 Chinese Medicine Research Project (No.20161110).
7

8
9 We thank Prof. Guo-Wei Xuan (Guangdong Provincial Hospital of Chinese Medicine,
10 Guangzhou, China), Profs. Ai-E Xu and Jun-Jun Shan (The Third Hospital of
11 Hangzhou, Hangzhou, China), Profs. Jun-ling Zhang and Hong-mei Wang (Affiliated
12 Hospital of Tianjin Chinese Medicine Academy) for their suggestions. We also thank
13 Mr Wen-Wei Ouyang and Dr Li-Ming Lu (Guangdong Provincial Hospital of Chinese
14 Medicine) for comments and suggestions on data management and the statistical
15 analysis plan.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2009. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2009.
2. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annu Rev Pathol*. 2012;7:385–422.
3. Ben Salem C, Hmouda H, Bouraoui K. Psoriasis. *The New England journal of medicine*. 2009 Oct 22;361(17):1710
4. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. *Molecular immunology*. 2015 Apr;64(2):313-23.
5. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *The Journal of investigative dermatology*. 2013 Feb;133(2):377-85.
6. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007 Jul 21;370(9583):263-71.
7. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). *Archives of dermatological research*. 2012 Mar;304(2):87-113.
8. Zhang CS, Yang L, Zhang AL, May BH, Yu JJ, Guo X. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. *J Altern Complement Med*. 2016 Mar;22(3):174-88.
9. May BH, Zhang AL, Zhou W, Lu CJ, Deng S, Xue CC. Oral herbal medicines for psoriasis: a review of clinical studies. *Chin J Integr Med*. 2012;18:172-8.
10. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, et al. Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. *Int J Dermatol*. 2014;53(11):1305–18.
11. Deng S, May BH, Zhang AL, Lu C, Xue CC. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. *Br J Dermatol*. 2013 Oct;169(4):769-82.
12. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal formulae in the management of psoriasis: systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs. *Phytother Res*. 2014 Apr;28(4):480-97.
13. Yang L, Zhang CS, May B, Yu J, Guo X, Zhang AL, et al. Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis. *Chin Med*. 2015 Sep 26;10:27.
14. Deng S, May BH, Zhang AL, Lu C, Xue CC. Phytotherapy in the management of

1
2
3 psoriasis: a review of the efficacy and safety of oral interventions and the
4 pharmacological actions of the main plants. *Arch Dermatol Res.* 2014
5 Apr;306(3):211-29.

6
7
8 15. Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C. Add-on effect of chinese
9 herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review. *Evid*
10 *Based Complement Alternat Med.* 2013;2013:673078.

11
12 16. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal medicine combined
13 with pharmacotherapy for psoriasis: a systematic review and meta-analysis. *Arch*
14 *Dermatol Res.* 2013 Apr;305(3):179-89.

15
16
17 17. Lu CJ, Yu JJ, Deng JW. Disease-syndrome combination clinical study of
18 psoriasis: present status, advantages, and prospects. *Chin J Integr Med.* 2012
19 Mar;18(3):166-71.

20
21 18. Han L, Peng Y, Zhao RZ, Feng B, Lu CJ. Effect of Yinxieling on proliferation of
22 HaCaT. *J Guangzhou Univ TCM* 2011; 28(2): 159-162.

23
24 19. Lu CZ, Wu XX, Liu FN. Effect of Yinxieling on PCNA expression and apoptosis
25 of keratinocyte. *Trad Chin Drug Res Clin Pharmacol* 2006; 17(5): 329-331.

26
27 20. Lei Wang, Yongjing, Huang, Minghua Wang. Clinical Observation of Yinxieling
28 Tablets for the Treatment of Psoriasis Vulgaris. *Journal of Guangzhou University of*
29 *Traditional Chinese Medicine.* 2009 Nov; 26(6): 520-5.

30
31 21. Dai YJ, Li YY, Zeng HM, Liang XA, Xie ZJ, Zheng ZA. Effect of Yinxieling
32 decoction on PASI, TNF- α and IL-8 in patients with psoriasis vulgaris. *Asian Pac J*
33 *Trop Med.* 2014 Aug;7(8):668-70.

34
35 22. Yan YH, Zhao RZ, Lu CJ. Optimization of Yinxieling Capsule with orthogonal
36 design. *Lishizhen Medicine and Materia Medica Research.* 2014; 25(11): 2763-5.

37
38 23. Wei Zhu, He Songmin, Yuan Xiaohong, Lu Chuanjian. Computerized Systematic
39 Pharmacological Research of Yinxieling Formula. *Traditional Chinese Drug Research*
40 *and Clinical Pharmacology.* 2011; 22(4): 379-82.

41
42 24. Yan YH, Lu CJ. Effect of modified Yinxieling on pustular psoriasis. *Trad Chin*
43 *Drug Res Clin Pharmacol* 2011; 22(6): 691-3.

44
45 25. Lu C, Deng J, Li L, Wang D, Li G. Application of metabolomics on diagnosis and
46 treatment of patients with psoriasis in traditional Chinese medicine. *Biochim Biophys*
47 *Acta.* 2014 Jan;1844(1 Pt B):280-8.

48
49 26. J.A. Wei, L. Han, C.J. Lu, et al., Formula PSORI-CM01 eliminates psoriasis by
50 inhibiting the expression of keratinocyte cyclin B2, *BMC Complement. Altern. Med.*
51 16 (1) (2016 Jul 29) 255.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27. Han L, Sun J, Lu CJ, Zhao RZ, Lu Y, Lin HJ, et al. Formula PSORI-CM01 inhibits the inflammatory cytokine and chemokine release in keratinocytes via NF- κ B expression. *Int Immunopharmacol*. 2017 Mar;44:226-233.
28. Psoriasis Group of Dermatology and Venereology: Chinese Medical Association. Clinical guidelines of psoriasis 2008. *Chin J Dermatol (Chin)*. 2009;42, 213-4.
29. Yao DN, Lu CJ, Wen ZH, Yan YH, Xuan ML, Li XY, Li G, et al. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. *Trials*. 2016 Mar 16;17(1):140.
30. Sedgwick P: What is intention to treat analysis? *BMJ* 2013, 346: f3662–f3662.
31. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. *American journal of clinical dermatology*. 2005;6(6):383-92.
32. Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. *Journal of the American Academy of Dermatology*. 2012 Oct;67(4):651-7.
33. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. *The Australasian journal of dermatology*. 2004 Aug;45(3):155-9.
34. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. *Sleep medicine*. 2012 Mar;13(3):285-9.
35. Farley E, Menter A. Psoriasis: comorbidities and associations. *Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia*. 2011 Feb;146(1):9-15.
36. Slobodin G, Rosner I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic arthropathy: where now? *The Israel Medical Association journal : IMAJ*. 2009 Jul;11(7):430-4.
37. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *The British journal of dermatology*. 2010 Sep;163(3):586-92.
38. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications. *Journal of medicine and life*. 2014 Oct-Dec;7(4):468-71.
39. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. *Journal of the American Academy of Dermatology*. 2015 Apr 14.

- 1
2
3 40. Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, et al. Psoriasis in the US
4 Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic
5 Use. *J Invest Dermatol*. 2015 Dec;135(12):2955-63.
6
7
8 41. Wen ZH, Xuan ML, Yan YH, Li XY, Yao DN, Li G. Chinese medicine combined
9 with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris
10 (CMCBCOP): study protocol for a randomized controlled trial. *Trials*. 2014 Jul
11 22;15:294.
12
13 42. Parker S, Zhang AL, Zhang CS, Goodman G, Wen Z, Lu C. Oral granulated
14 Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris:
15 study protocol for a double-blind, randomized placebo controlled trial. *Trials*. 2014
16 Dec 19;15:495.
17
18 43. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K,
19 Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR,
20 Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D.
21 SPIRIT: Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern*
22 *Med* 2013, 2013:200–207.
23
24 44. Moher D, Schulz KF, Altman DG: CONSORT. The CONSORT statement:
25 revised recommendations for improving the quality of reports of parallel group
26 randomized trials. *BMC Med Res Methodol* 2001, 1:2.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure captions:

Figure 1. Flowchart of the study

Table captions:

Table 1. Schedule for treatment and outcome measure

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of the study.

297x420mm (300 x 300 DPI)



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	7, Table.1
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	7-8
	7b	When applicable, explanation of any interim analyses and stopping guidelines	9
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9

1				
2				
3		assessing outcomes) and how		
4		11b If relevant, description of the similarity of interventions		
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes		9
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses		9
7				
8	Results			
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and		9
10	diagram is strongly	were analysed for the primary outcome		
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons		
12	Recruitment	14a Dates defining the periods of recruitment and follow-up		12
13		14b Why the trial ended or was stopped		
14				
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group		
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was		
17		by original assigned groups		
18				
19	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its		
20	estimation	precision (such as 95% confidence interval)		
21		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended		
22	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing		
23		pre-specified from exploratory		
24				
25	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)		
26				
27	Discussion			
28	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		
29	Generalisability	21 Generalisability (external validity, applicability) of the trial findings		
30	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		
31				
32	Other information			
33	Registration	23 Registration number and name of trial registry		1
34	Protocol	24 Where the full trial protocol can be accessed, if available		
35	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders		12
36				

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	15
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	1, 6,15

Introduction

5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5
8		6b	Explanation for choice of comparators	5
10	Objectives	7	Specific objectives or hypotheses	5
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
16	Methods: Participants, interventions, and outcomes			
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6,7
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6,8
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	12
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, Table 1
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6-8, Figure 1

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
7				
8	Methods: Assignment of interventions (for controlled trials)			
9				
10	Allocation:			
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10,11
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10,11
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	10,11
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	10,11
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
29				
30				
31				

Methods: Data collection, management, and analysis

32				
33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11,12
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11,12
40				
41				
42				
43				
44				
45				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	12
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11,12
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	1, 6
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	6
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	6
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	NA
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	1
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	15
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
36				
37				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol for a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014475.R3
Article Type:	Protocol
Date Submitted by the Author:	29-Jul-2017
Complete List of Authors:	Deng, Jingwen; Dermatology Yao, Danni; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Lu, Chuan-jian ; Guangdong Provincial Hospital of Traditional Chinese Medicine, Department of dermatology Wen, Zehuai; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Yan, YuHong; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology He, Ziyang; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Wu, Huimei; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology Deng, Hao; Guangdong Provincial Hospital of Chinese Medicine, Department of Dermatology
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, Chinese Herbal Medicine, Clinical Trial, Protocol

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12

Oral Chinese Herbal Medicine for Psoriasis Vulgaris: Protocol for a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial

Jingwen Deng^{1,2,†}, Danni Yao^{1,2,†}, Chuanjian Lu^{1,2,3*}, Zehuai Wen⁴,
Yuhong Yan^{1,2}, Ziyang He¹, Huimei Wu^{1,2}, Hao Deng^{1,2}

Abstract

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Introduction: Psoriasis vulgaris (PV) is a common skin disease that is characterized by persistent localized erythematous scaly plaques. Yinxieling is a Chinese herbal formula for psoriasis that has been used for more than 20 years in China. To facilitate application, PSORI-CM01 was developed based on the optimization and simplification of Yinxieling tablets performed in a previous study and in clinical practice. However, the scientific evidence regarding whether PSORI-CM01 is more effective for psoriasis than the original Yinxieling remains insufficient. Therefore, we designed a randomized clinical trial to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granules compared with those of Yinxieling tablets for the treatment of patients with psoriasis.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Methods and analysis: This on-going study is a two-arm parallel, randomized, double-blind, double-dummy clinical trial. Five hundred fifty-six participants with psoriasis will be recruited and then randomly allocated into two groups in a 1:1 ratio. Participants in PSORI-CM01 group will receive a 5.5-g granule of PSORI-CM01 twice daily and five placebo tablets three times daily for 12 weeks. The participants in the Yinxieling group will receive five Yinxieling tablets three times daily and a placebo granule twice daily for 12 weeks. The primary outcome is the reduction of the Psoriasis Area and Severity Index (PASI). The secondary outcomes include relapse rate, visual analogue scale (VAS) scores, body surface area (BSA), and the Dermatology Life Quality Index (DLQI). Cost effectiveness analysis will be performed from a health and community care provider perspective.

47
48
49
50
51
52
53
54
55

Ethics and dissemination: This research protocol had been reviewed and approved by the institutional review boards of three trial centres (Guangdong Provincial Hospital of Chinese Medicine (B2014-026-01), Affiliated Hospital of Tianjin Chinese Medicine Academy (2014-KY-001) and Third Hospital of Hangzhou (B2014-026-01)). The findings will be disseminated to the public through conference presentations and open access journals.

56
57

Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-14005185

58
59

[†]Jingwen Deng and Danni Yao contributed equally to this work.

60
1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*** Correspondence:**

Chuanjian Lu

luchuanjian888@vip.sina.com

Strengths and limitations of this study

- We are performing a trial to provide evidence regarding the clinical effectiveness of a Chinese medicine treatment for psoriasis before and after optimization and simplification.
- There is no absolute placebo control, which means that this trial will be unable to assess the absolute efficacy and will assess only the relative efficacy.
- For broad use of the herbal formula, we designed PSORI-CM01 based on the rule “treated from the blood”, which is related to the core pathogenesis of psoriasis in Traditional Chinese Medicine (TCM) theory.
- There is no stratification based on TCM syndromes in the design of the trial because PSORI-CM01 can be applied to the blood heat, blood stasis, and blood dryness syndromes of psoriasis.

Authors' information

1. Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China;
2. Psoriasis clinical and basic research team, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou 510120, China;
3. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 510120, China
4. Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Authors' contact information

JingWen Deng, e-mail: s6891@163.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

DanNi Yao, e-mail: yaodanni1984@163.com,

Tel:+8620-81887233-30603, Fax:+8620-81874903

ChuanJian Lu, e-mail: luchuanjian888@vip.sina.com

Tel:+8620-81887233-31223, Fax:+8620-81874903

ZeHuai Wen, e-mail: wenzh@gzucm.edu.cn,

Tel:+8620-81887233-31227, Fax:+8620-81874903

YuHong Yan, e-mail: yanyuhong7966@139.com,

2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tel:+8620-81887233-30603, Fax: +8620-81874903

ZiYang He, e-mail: ziyanghe@qq.com,

Tel:+8620-81887233-31227, Fax:+8620-81874903

HuiMei Wu, e-mail: 691892927@qq.com,

Tel:+8620-81887233-30603, Fax: +8620-81874903

Hao Deng, e-mail: 563435624@qq.com

Tel:+8620-81887233-35934, Fax:+8620-81874903

For peer review only

Background:

Psoriasis is a chronic, immune-mediated, inflammatory skin disease characterized by erythema, scale and redness, and thickening and scaling of the skin. The main histopathologic change of psoriasis is accelerated keratinocyte cell proliferation^{1, 2}. However, the cause of this disease remains unknown. Although an early concept of the pathogenesis of psoriasis focused on the proliferation and differentiation of keratinocytes, recent studies have recognized that dysregulation of the immune system plays a critical role in the development of psoriasis. The interactions between dendritic cells, T cells, keratinocytes, neutrophils, and the cytokines released from immune cells are the core mechanism of the development of psoriasis³. Genetic, environmental and behavioural factors are thought to be triggers that contribute to the onset of psoriasis⁴. The prevalence of psoriasis in adults is estimated to range from 0.91% to 8.5% worldwide⁵. Clinically, psoriasis vulgaris is the most common subtype of psoriasis and affects approximately 90% of patients⁶.

The most common treatments for psoriasis include topical medication, ultraviolet light, systematic drugs and biologics. Topical medications, such as corticosteroids, retinoid and vitamin D analogues, are considered to be first-line therapies for psoriasis vulgaris. Systematic drugs are for severe psoriasis, while ultraviolet light and biologics are used when applicable and necessary⁷.

A series of systematic reviews have demonstrated that Chinese Medicine contains an effective therapy for psoriasis⁸⁻¹⁶. Yinxieling tablets, which are a Chinese herbal medicine compound preparation with 10 ingredients (i.e., *angelica sinensis*, *radix paeoniae rubra*, *chloanthus spicatus*, *smoked plum*, *radix rehmanniae recen*, *ligusticum wallichii*, *radices lithospermi*, *curcuma zedoary*, and *rhizome smilacis glabrae*, *liquorice*) that is used for the treatment of psoriasis, was developed by the National Medical Master Guo-wei Xuan, who is a well-known Chinese medicine doctor. These tablets were formulated according to traditional Chinese medicine theory and are theoretically effective and safe. In TCM theory, three syndromes of psoriasis are generally acknowledged: blood stasis, blood heat, and blood dryness type. In the acute stage, the pathogenesis of psoriasis vulgaris is mostly blood heat that is obstructed on the surface of the skin. In the chronic stage, the pathogenesis of psoriasis vulgaris is blood deficiency that develops into dryness that prohibits the nourishing of the skin or blood stasis that obstructs blood flow in skin collaterals. Therefore, activating blood circulation and removing blood stasis should be the focus of curing of psoriasis. Yinxieling tablets play the role of activating blood circulation and removing blood stasis in the treatment of psoriasis¹⁷.

In the recent 20 years of clinical practice, Yinxieling tablets have been extensively used for the treatment of psoriasis and have exhibited a promising clinical efficacy in terms of relieving the symptoms of psoriasis and reducing the relapsing rate. Molecular biological technologies have been used to analyse the pharmacological

1
2
3 mechanisms of multiple ingredients in Yinxieling tablets^{18, 19}. These studies have
4 demonstrated that Yinxieling tablets are involved in the regulation of
5 immune-mediated cells and the interaction of cellular cytokines, which has revealed
6 the potential mechanism of Yinxieling tablets in the treatment of psoriasis. In the
7 exploration of the molecular and pharmacological mechanisms of Yinxieling tablets,
8 two clinical trials have been performed to confirm their clinical effectiveness. In
9 Wang's study, 24 patients with psoriasis were equally randomized into the following
10 two groups: a treatment group that received Yinxieling tablets for eight weeks and a
11 control group that received acitretin capsules for eight weeks. The therapeutic effect
12 of the Yinxieling tablets in the treatment of psoriasis was similar to that of the
13 acitretin capsules, but fewer side effects appeared in the Yinxieling tablet group²⁰. In
14 Dai's study, 90 patients in observation groups were treated with Yinxieling, and
15 30 patients in a control group were treated with placebo for 8 weeks. The result
16 revealed that the Yinxieling decoction had a therapeutic effect on psoriasis vulgaris²¹.
17 However, there are limitations to the further development of Yinxieling because of its
18 complex compounds.

19 To expand the application of Yinxieling, an optimized formula, i.e., PSORI-CM01
20 (former name YXBCM01), was developed. This formula is composed of only seven
21 ingredients (i.e., *radix paeoniae rubra*, *smoked plum*, *chloranthus spicatus*, *radices*
22 *lithospermi*, *curcuma zedoary*, *rhizome smilacis glabrae*, and *liquorice*) of the
23 Yinxieling tablet that were found to have positive correlations with pharmacodynamic
24 indicators based on a computerized systematic pharmacological method and
25 orthogonal experiments^{22, 23}. An observational study revealed that two months of
26 treatment with PSORI-CM01 for psoriasis vulgaris reduced the PASI and DLQI
27 scores with no adverse events²⁴. Another 12-week observational study revealed that
28 the PASIs of patients with psoriasis were reduced after PSORI-CM01 treatment, and
29 the metabolic variations were observed in patients with psoriasis before and after
30 PSORI-CM01 treatment²⁵. Our previous study demonstrated that PSORI-CM01 can
31 reduce keratinocyte proliferation in vitro and inhibit epidermal hyperplasia in an
32 imiquimod (IMQ)-induced psoriasis-form mouse model²⁶. The PSORI-CM01 formula
33 can also affect the IL-17/IL-23 axis and inhibit the expression of cytokines and
34 chemokines and thus improve inflammatory conditions in the dermic
35 microenvironment²⁷.

36 However, the previous studies of PSORI-CM01 are all based on preliminary clinical
37 observations and animal experiments. Whether the clinical efficacy and safety of
38 PSORI-CM01 granules are better than those of its prototype, i.e., the Yinxieling tablet,
39 remains uncertain. Therefore, a rigorously designed randomized controlled trial to
40 determine whether PSORI-CM01 is more effective than the Yinxieling tablet and to
41 investigate the efficacy and safety of this new formula is warranted.

42 Method

43 5

Design

This is a double-dummy, double-blind, randomized, controlled trial to investigate the efficacy and safety of the new formula PSORI-CM01 granule compared with its prototype, the Yinxieling tablet. This study will be performed in three centres in China: the Guangdong Provincial Hospital of Chinese Medicine, the Affiliated Hospital of Tianjin Chinese Medicine Academy, and the Third Hospital of Hangzhou. Because Yinxieling tablets and PSORI-CM01 granules have different preparation forms, a double-dummy, double-blind trial design was selected to guarantee rigorous blinding. The study procedure consists of three components, i.e., an initial screening, a treatment period, and a follow-up period. In the initial screening, patients with psoriasis will be recruited via a dermatology clinic for physical examination and inclusion assessment. A two-week run-in period may be requested depending on the results of the assessments. If eligible, written informed consent will be requested of the participants. Additional consent provisions for collection and use of participant data and biological specimens will be requested as well. All details of the informed consent will be clearly explained to the participant to assure their understanding. Once informed consent is obtained, a participant will be given a random sequence number. All participants will be allocated into two groups at a ratio of 1:1. One group will receive PSORI-CM01 granules with Yinxieling placebo tablets, and the other group will receive Yinxieling tablets with PSORI-CM01 placebo granules (Fig. 1). We will collect patients' information about TCM syndromes before and after the treatment. Target lesions will be recorded with digital photographs taken with SLR cameras at every visit.

The trial protocol was approved by the Guangdong Provincial Hospital of Chinese Medicine ethics committee, and registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-14005185).

Eligibility criteria

Inclusion criteria

The patients must meet all of the following criteria at the time of randomization to be eligible for recruitment:

- (1) The patients must meet the criteria for the diagnosis of psoriasis vulgaris referred to in the Clinical Guidelines of Psoriasis 2008 reported by the Chinese Medical Association²⁸.
- (2) Male and female patients must be between 18 and 65 years old.
- (3) A PASI of more than 3 and less than 30, and a BSA of less than 30% are required.
- (4) Informed consent must be obtained.

Exclusion criteria

The trial exclusion criteria include any of the following:

- (1) Psoriatic lesions can only be seen on the face, scalp, nails, anus, mucus and

1
2
3 palmar-plantar areas.

4 (2) Acute progressive psoriasis, an erythroderma tendency, and psoriatic arthritis are
5 present.

6
7 (3) Patients who are pregnant, lactating, and those who plan to become pregnant
8 within a year will be excluded.

9
10 (4) Those with an SAS more than 50 or an SDS more than 53, and those with other
11 psychiatric disorders will be excluded.

12
13 (5) Those with a history of primary cardiovascular, respiratory, digestive, urinary,
14 endocrinologic and haematologic diseases that cannot be controlled with ordinary
15 treatments will be excluded. Those with malignant diseases, infections, electrolyte
16 imbalances, and acid-base disturbances will be excluded. Patients with the following
17 clinical test results will be excluded: an AST or ALT 3 times greater than the normal
18 upper limit, creatinine 1.5 times greater than the normal upper limit; haemoglobin
19 elevated by 20 g/L above the normal upper limit; a platelet count less than $75.0 \times 10^9/L$;
20 a white blood cell count less than $3.0 \times 10^9/L$, and other abnormal laboratory test
21 results, as assessed by the investigators, which are not suitable for this clinical study.

22
23 (6) Patients who are allergic to any medicine or ingredients used in this study will be
24 excluded.

25
26 (7) Those participating other clinical trials and those who have participated in trials
27 within 1 month will be excluded.

28
29 (8) Patients who have used corticosteroids or retinoic acid acting on the skin over the
30 previous 2 weeks, those on systemic therapy or phototherapy (UVB and PUVA) with
31 the previous 4 weeks, and those on biological therapy over the previous 12 weeks will
32 be excluded.
33
34
35
36
37

38 **Interventions**

39 **PSORI-CM01 group**

40 Participants in PSORI-CM01 group will receive 5.5 PSORI-CM01 granules twice
41 daily after meals and five placebo tablets three times daily after meals for 12 weeks.

42 **Yinxieling group**

43 Participants in Yinxieling group will receive five Yinxieling tablets three times daily
44 after meals and placebo granules 5.5 g twice daily after meals for 12 weeks.
45
46
47
48
49

50 **Outcome measures**

51 **Primary outcome**

52 The primary outcome is the reduction in the PASI score, which will be calculated as
53 follows:
54

55 Reduction of the PASI = PASI at baseline - PASI at week 12.

56 The PASI scores of the patients will be assessed every 2 weeks during the treatment
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

period and every 4 weeks during the follow-up period. The PASI reduction calculated at week 12 will be considered the primary outcome.

Secondary outcomes

The secondary outcome measures include relapse rate, BSA, VAS and DLQI. The VAS and BSA will be assessed every 2 weeks during the treatment period and every 4 weeks in the follow-up period. The DLQI will be assessed by the patients every 4 weeks during the treatment period. In the follow-up period, the DLQI will only be assessed at the last week (the 24th week). Laboratory reports were also be monitored until the last visit (Table. 1).

Health economics

An economic evaluation will be performed from the perspective of the Health Department of Guangdong Province and will occur in the form of cost-utility analysis and will be conducted using utility values obtained from the DLQI preference-based quality of life measure. The DLQI is a dermatology-specific quality of life instrument for routine clinical use. This instrument is a validated questionnaire with a simple 10-question format. At present, the DLQI is the most frequently used instrument for evaluating the effects of skin disease and related treatments on patients' lives. The DLQI will be measured at baseline and at 4 and 16 weeks for utility-based quality of life evaluation in this study. Resource use will include intervention costs, healthcare costs and community service costs, which will be calculated for each trial participant. We will analyse an incremental cost-effectiveness ratio (ICER) of the cost per patient by calculating the incremental mean difference in costs between the two trial arms and the incremental difference in patient outcome after the follow-up.

Sample size

Due to the lack of studies evaluating the effects of PSORI-CM01 granule and Yinxieling tablets on psoriasis that are available for sample size calculation, we performed the sample calculation based on our previous study's results and experts' opinions²⁹. The superiority-test for two means was used for the sample size calculation. We assumed that the superiority margin of the PASI was 1.5, and the standard deviations were 1.1 and 2.5 for the PSORI-CM01 granules and Yinxieling tablets, respectively. The significance level (alpha) of the test was 0.025, and statistical power was 80%. A sample size of 236 was deemed necessary for the each arm after the calculations. Considering a 15% loss to follow-up, 278 patients are needed in each arm for a total of 556 patients. The PASW Statistics software (version 18.0; IBM Inc., Chicago, IL, USA) was used for the calculations.

8

Table 1 Schedule for treatment and outcome measurements

	Period Time points	Enrolment	Allocation	Treatment period						Follow-up period		
		-1w	0w	2w	4w	6w	8w	10w	12w	16w	20w	24w
Enrolment	Eligibility screening	●										
	Informed consent	●										
	Characteristic	●										
	Medical history	●										
	Laboratory examination		●						●			
	Biological specimens		●						●			
	Random allocation		●									
	Intervention	PSORI-CM01 granules and placebo tablets		☆	—————						☆	
Yinxieling tablets and placebo granules			★	—————						★		
Assessment	TCM syndrome		●						●			●
	PASI	●	●	●	●	●	●	●	●	●	●	●
	BSA	●	●	●	●	●	●	●	●	●	●	●
	VAS	●	●	●	●	●	●	●	●	●	●	●
	DLQI		●						●			●
	SAS	●										
	SDS	●										
	Safety assessment	●	●	●	●	●	●	●	●	●	●	●

☆: For PSORI-CM01 group

★: For Yinxieling group

Randomisation and allocation

Eligible patients will be randomly assigned, in a 1:1 ratio, to one of the two treatment groups (PSORI-CM01 group or Yinxieling group) at the second visit through central randomization. Equal randomization will be conducted using a computer-generated random allocation sequence through the stratified block randomization method of the SAS software (version 9.12; SAS Institute, Inc., Cary, NC, USA) by the Key Unit of Methodology in Clinical Research (KUMCR) of Guangdong Provincial Hospital of Chinese Medicine. Allocation concealment will be ensured, as the randomization code will be released by the Interactive Web Response System for Chinese Medicine Trials (IWRS-CMT), which was a verified online randomization facility established by the KUMCR (<http://www.gztcmgcp.net/sjxt/login.asp>). After that, the participants will be randomly allocated to two different treating groups.

Test drugs and blinding

After preliminary clinical observations, we changed the form of the PSORI-CM01 formula to granules because the preparation of oral granules normally involves smooth, quick water absorption and swelling properties that allow for easy swallowing.

The PSORI-CM01 granules and the matching placebo granules used in the trial were prepared by Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, Jiangsu Province, China). The Yinxieling tablets and the matching placebo tablets were prepared by Kangyuan Pharmaceutical Co., Ltd. (Guangzhou, Guangdong Province, China). All of the above drugs met the requirements of Good Manufacturing Practice (GMP). The main ingredients of the placebo granules and the placebo tablets are maltodextrin, lactose, and a natural edible pigment, and these ingredients are similar to those of the PSORI-CM01 granules and Yinxieling tablets in appearance, weight, and taste.

The practitioners will be blind to the allocation arm, and the arms will have similar medical procedures. Moreover, the evaluations of the participants and the analysis of the results will be performed by physician assessors and statisticians who are blinded to the group allocation.

Statistical analysis

All analyses will be performed with PASW Statistics and SAS 9.2 software by a statistician who is blinded to the random allocation of groups. Intent-to-treat (ITT)-based statistical analyses with 95% confidence intervals will be performed. The

10

1
2
3 ITT analyses will include all of the patients who are randomized³⁰. Safety analysis
4 will be undertaken by analysing the frequency of adverse events that are suspected to
5 be related to the treatment. The various parameters observed will be compared using
6 the chi-square test for non-continuous variables (i.e., the primary outcome and relapse
7 rate), and t-tests and analyses of variance (ANOVAs) will be used for the continuous
8 variables. Rank or skewed (not follow normality) data in these analyses will be
9 examined using Wilcoxon signed-rank test. To distinguish the treatment effect and the
10 time effect, repeated measures analysis of variance of the change from baseline will
11 be performed for the different time point assessments. A subgroup analyses will be
12 performed based on the severity of the disease and the TCM syndromes. Statistical
13 significance will be established at $P < 0.05$.

21 22 **Adverse events**

23 Before the beginning of, and after 12 weeks of treatment, medical histories will be
24 recorded for each patient, and standard laboratory examinations and specific
25 laboratory investigations will also be performed. The standard laboratory
26 examinations will include the following: haematologic parameter assessment
27 (haemoglobin, and red blood cell, platelet, and white blood cell counts); urinalysis
28 (proteins, and red and white blood cell biochemical assessments (serum electrolytes),
29 indices of renal function (creatinine and urea) and hepatic function (alkaline
30 phosphatase, aspartate amino transferase, alanine amino transferase, and
31 g-glutamyl-transpeptidase); and electrocardiograms. The specific laboratory
32 investigations mainly include the serum cytokine levels.

33 All adverse events will be collected and graded for severity and potential relation to
34 the treatments by assessors at every visit. The safety evaluations include the incidence
35 of treatment-induced or serious adverse events, dropout due to adverse events, and
36 laboratory parameter changes. In cases of severe adverse effects, all drugs in this trial
37 will be immediately discontinued.

48 49 **Data management**

50 All physicians, assessors and research assistants will attend training workshops before
51 the conduction of trial. Investigators in different centre will all be required to follow
52 the standard operating procedures. The quality controllers from the contract research
53 organization (CRO) Guangdong International Clinical Research Center of Chinese
54 Medicine (Guangzhou, China) will perform regular monitoring in each centre

1
2
3 throughout the trial. All study data will be managed as detailed in the full trial
4 protocol and in accordance with the data management plan, which was developed by
5 the Data Monitoring Committee of the Guangdong Provincial Hospital of Chinese
6 Medicine (GPHCM). The data collection will include all information in the case
7 report forms. The data will be entered using the double entry method. To ensure
8 data quality and data consistency between the source data and the data entered into
9 the database, two research assistants will independently input the data from the CRFs
10 into database using a prespecified database software that was developed by the Data
11 Monitoring Committee. The Data Monitoring Committee will assess the safety data
12 and the critical efficacy outcomes after the trial is finished.
13
14
15
16
17
18
19
20
21

22 Discussion

23
24 Psoriasis is a disease of immune abnormality that progresses slowly over a long
25 period with frequent symptom recurrences. Psoriasis causes detrimental effects on
26 the quality of life of both adults and children. Elevated rates of various
27 psychopathologies, including poor self-esteem, sexual dysfunction, anxiety,
28 depression, and suicidal ideation, have been reported in patients with psoriasis³¹⁻³⁵.
29 Psoriasis is not a disease that only affects the skin. Increasing evidence supports the
30 recognition of psoriasis as a chronic multisystem inflammation disorder with
31 multiple associated comorbid conditions. Comorbidities linked to psoriasis include
32 psoriatic arthritis, cardiovascular diseases, obesity, metabolic syndrome, malignancy,
33 hypertension, and inflammatory bowel disease²⁵. Psoriatic arthritis (PsA) is an
34 erosive and deforming joint disease that is associated with psoriasis and affects 7%
35 to 42% of the psoriasis population³⁶. PsA-induced joint damaging complications not
36 only lead to lower articular function and higher mortality but also affect patients'
37 abilities to work and their social relationships³⁷. In patients with severe psoriasis, the
38 life expectancy is reduced by 5 years primarily due to cardiovascular disease³⁷.
39 Additionally, psoriasis has a strong connection with metabolic syndrome, which
40 makes it a marker for increased risks of the morbidities and mortalities associated
41 with these diseases³⁸. Psoriasis can also cause substantial economic loss. According
42 to a systematic literature review conducted by the American Academy of
43 Dermatology, the total direct and indirect burden of psoriasis is estimated to be \$35.2
44 billion in the U.S. per annum³⁹.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The treatments used for moderate to severe psoriasis (i.e., phototherapy and oral
4 systemic and biologic therapies) were received by 27.3% of the total psoriasis
5 sample, of whom 37.2% used biologics⁴⁰. Orally
6 administered Chinese herbal medicine has been used for the clinical management
7 of psoriasis for years. However, a number of high-quality clinical trials are needed
8 before Chinese herbal medicine can be recommended for psoriasis. We conducted a
9 series of systematic reviews to evaluate the effects of Chinese herbal medicine alone
10 and in combination with pharmacotherapy for psoriasis⁸⁻¹⁶. The results revealed that
11 there is promising evidence of positive effects from a number of studies of
12 multi-herb formulations.
13
14
15
16
17
18
19

20 We changed the form of the PSORI-CM01 formula to granules in this study.
21 Considering too many blood-activating and stasis-dissolving drugs would cause
22 consumption of Qi, we removed *angelica sinensis*, *radix rehmanniae recen*,
23 *ligusticum wallichii* from Yinxieling. The remain seven herbs turned to be
24 PSORI-CM01. Tablets containing micronized Chinese herbal medicine are not
25 suitable for immediate release. Granules are solid when stored and will swell and gel
26 via water absorption. Additionally, granules from simplified formulations offer great
27 opportunities to improve continuous processes, present performances comparable to
28 more complicated formulations and are able to correspond to the requirements of the
29 authorities. In this study, the micro-structure and tensile strength of the granules
30 resembled those of the tablets formed from the original ungranulated powder.
31
32
33
34

35 To our knowledge, this trial is the first study to compare the clinical effectiveness of
36 Chinese medicine treatment for psoriasis before and after optimization and
37 simplification. Moreover, we aim to provide supporting data for the effectiveness of
38 the PSORI-CM01 granule that resulted from the optimization of Yinxieling tablet as
39 determined in a previous study and clinical practice. This study is the third clinical
40 trial that our research team has conducted on the effectiveness of the PSORI-CM01
41 granule for patients with psoriasis. The first study compared oral the PSORI-CM01
42 granule plus topical sequential therapy for moderate to severe psoriasis and was a
43 double-blind, randomized placebo-controlled trial that evaluated the effectiveness of
44 PSORI-CM01 combined with usual topical therapy compared with the usual topical
45 therapy that is used in the clinical practice of Western medicine alone^{29, 41}. The second
46 study evaluated oral PSORI-CM01 granule plus topical calcipotriol for psoriasis
47 relative to placebo plus topical calcipotriol over 12 weeks; this study was a pilot
48 randomized, placebo-controlled, double-blinded trial⁴². These two trials aimed to
49 evaluate the benefits of the addition of PSORI-CM01 granules compared with
50 conventional treatments of psoriasis. In contrast to the above two trials, the present
51 clinical trial protocol acts as the foundation for evaluating the treatment of psoriasis
52
53
54
55
56
57
58
59
60

1
2
3 with Chinese medicine.

4 For facilitating appropriate reference standards for scientific, ethical and safety issues
5 before the trial begins, this protocol has been developed according to Standard
6 Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 and
7 Consolidated Standards of Reporting Trials (CONSORT) statement^{43, 44}.
8
9
10

11 **Ethics and dissemination**

12 This research protocol had been reviewed and approved by the institutional review
13 boards of three trial centers (Guangdong Provincial Hospital of Chinese Medicine
14 (B2014-026-01), Affiliated Hospital of Tianjin Chinese Medicine Academy
15 (2014-KY-001) and Third Hospital of Hangzhou (B2014-026-01)).

16 The Biological Resource Center of Guangdong Provincial Hospital of Chinese
17 Medicine approved the biobank procedure. Written informed consent will be given by
18 participants. The informed consent forms for participation in clinical trial and the
19 biobanking part are separated. The results will be disseminated to the public through
20 conference presentations and open access journals.
21
22
23
24
25
26
27
28

29 **Trial status**

30 The recruitment phase began in November 2014. Thus far, 63 patients have been
31 recruited. The estimated end date for this study is in October 2018.
32
33
34

35 **Abbreviations**

36 ANOVA: Analysis of variance

37 BSA: Body Surface Area

38 CRO: contract research organization

39 DLQI: Dermatology Life Quality Index

40 IMQ: imiquimod

41 ITT: Intent-to-treat

42 IWRS-CMT: Interactive Web Response System for Chinese Medicine Trials

43 KUMCR: Key Unit of Methodology in Clinical Research

44 PASI: Psoriasis Area and Severity Index

45 SAS: Self-rating Anxiety Scale

46 SDS: Self-rating Depression Scale

47 TCM: Traditional Chinese Medicine

48 VAS: Visual analogue scale
49
50
51
52
53
54
55
56
57
58
59
60

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

Jingwen Deng, Danni Yao and Chuanjian Lu drafted the manuscript. Chuanjian Lu and Zehuai Wen participated in the design of the study, Danni Yao, Yuhong Yan, Ziyang He, Huimei Wu and Hao Deng coordinate the study. All authors participated in, read, and approved the final manuscript.

Acknowledgments

This research was supported by grants of the National Key Technology R&D Program for the 12th Five-year Plan of Ministry of Science and Technology, China (No. 2013BAI02B03), Provincial Science and Technology Project of Guangdong Province, China (No.2015B020211013) and Guangdong Provincial Bureau of traditional Chinese Medicine Research Project (No.20161110).

We thank Prof. Guo-Wei Xuan (Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China), Profs. Ai-E Xu and Jun-Jun Shan (The Third Hospital of Hangzhou, Hangzhou, China), Profs. Jun-ling Zhang and Hong-mei Wang (Affiliated Hospital of Tianjin Chinese Medicine Academy) for their suggestions. We also thank Mr Wen-Wei Ouyang and Dr Li-Ming Lu (Guangdong Provincial Hospital of Chinese Medicine) for comments and suggestions on data management and the statistical analysis plan.

References

1. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2009. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2009.
2. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annu Rev Pathol*. 2012;7:385–422.
3. Ben Salem C, Hmouda H, Bouraoui K. Psoriasis. *The New England journal of medicine*. 2009 Oct 22;361(17):1710
4. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. *Molecular immunology*. 2015 Apr;64(2):313-23.
5. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *The Journal of investigative dermatology*. 2013 Feb;133(2):377-85.
6. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007 Jul 21;370(9583):263-71.
7. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). *Archives of dermatological research*. 2012 Mar;304(2):87-113.
8. Zhang CS, Yang L, Zhang AL, May BH, Yu JJ, Guo X. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. *J Altern Complement Med*. 2016 Mar;22(3):174-88.
9. May BH, Zhang AL, Zhou W, Lu CJ, Deng S, Xue CC. Oral herbal medicines for psoriasis: a review of clinical studies. *Chin J Integr Med*. 2012;18:172-8.
10. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, et al. Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. *Int J Dermatol*. 2014;53(11):1305–18.
11. Deng S, May BH, Zhang AL, Lu C, Xue CC. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. *Br J Dermatol*. 2013 Oct;169(4):769-82.
12. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal formulae in the management of psoriasis: systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs. *Phytother Res*. 2014 Apr;28(4):480-97.
13. Yang L, Zhang CS, May B, Yu J, Guo X, Zhang AL, et al. Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis. *Chin Med*. 2015 Sep 26;10:27.
14. Deng S, May BH, Zhang AL, Lu C, Xue CC. Phytotherapy in the management of

1
2
3 psoriasis: a review of the efficacy and safety of oral interventions and the
4 pharmacological actions of the main plants. *Arch Dermatol Res.* 2014
5 Apr;306(3):211-29.

6
7
8 15. Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C. Add-on effect of chinese
9 herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review. *Evid*
10 *Based Complement Alternat Med.* 2013;2013:673078.

11
12 16. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal medicine combined
13 with pharmacotherapy for psoriasis: a systematic review and meta-analysis. *Arch*
14 *Dermatol Res.* 2013 Apr;305(3):179-89.

15
16
17 17. Lu CJ, Yu JJ, Deng JW. Disease-syndrome combination clinical study of
18 psoriasis: present status, advantages, and prospects. *Chin J Integr Med.* 2012
19 Mar;18(3):166-71.

20
21
22 18. Han L, Peng Y, Zhao RZ, Feng B, Lu CJ. Effect of Yinxieling on proliferation of
23 HaCaT. *J Guangzhou Univ TCM* 2011; 28(2): 159-162.

24
25 19. Lu CZ, Wu XX, Liu FN. Effect of Yinxieling on PCNA expression and apoptosis
26 of keratinocyte. *Trad Chin Drug Res Clin Pharmacol* 2006; 17(5): 329-331.

27
28
29 20. Lei Wang, Yongjing, Huang, Minghua Wang. Clinical Observation of Yinxieling
30 Tablets for the Treatment of Psoriasis Vulgaris. *Journal of Guangzhou University of*
31 *Traditional Chinese Medicine.* 2009 Nov; 26(6): 520-5.

32
33 21. Dai YJ, Li YY, Zeng HM, Liang XA, Xie ZJ, Zheng ZA. Effect of Yinxieling
34 decoction on PASI, TNF- α and IL-8 in patients with psoriasis vulgaris. *Asian Pac J*
35 *Trop Med.* 2014 Aug;7(8):668-70.

36
37
38 22. Yan YH, Zhao RZ, Lu CJ. Optimization of Yinxieling Capsule with orthogonal
39 design. *Lishizhen Medicine and Materia Medica Research.* 2014; 25(11): 2763-5.

40
41 23. Wei Zhu, He Songmin, Yuan Xiaohong, Lu Chuanjian. Computerized Systematic
42 Pharmacological Research of Yinxieling Formula. *Traditional Chinese Drug Research*
43 *and Clinical Pharmacology.* 2011; 22(4): 379-82.

44
45 24. Yan YH, Lu CJ. Effect of modified Yinxieling on pustular psoriasis. *Trad Chin*
46 *Drug Res Clin Pharmacol* 2011; 22(6): 691-3.

47
48 25. Lu C, Deng J, Li L, Wang D, Li G. Application of metabolomics on diagnosis and
49 treatment of patients with psoriasis in traditional Chinese medicine. *Biochim Biophys*
50 *Acta.* 2014 Jan;1844(1 Pt B):280-8.

51
52 26. J.A. Wei, L. Han, C.J. Lu, et al., Formula PSORI-CM01 eliminates psoriasis by
53 inhibiting the expression of keratinocyte cyclin B2, *BMC Complement. Altern. Med.*
54 16 (1) (2016 Jul 29) 255.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27. Han L, Sun J, Lu CJ, Zhao RZ, Lu Y, Lin HJ, et al. Formula PSORI-CM01 inhibits the inflammatory cytokine and chemokine release in keratinocytes via NF- κ B expression. *Int Immunopharmacol*. 2017 Mar;44:226-233.
28. Psoriasis Group of Dermatology and Venereology: Chinese Medical Association. Clinical guidelines of psoriasis 2008. *Chin J Dermatol (Chin)*. 2009;42, 213-4.
29. Yao DN, Lu CJ, Wen ZH, Yan YH, Xuan ML, Li XY, Li G, et al. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. *Trials*. 2016 Mar 16;17(1):140.
30. Sedgwick P: What is intention to treat analysis? *BMJ* 2013, 346: f3662–f3662.
31. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. *American journal of clinical dermatology*. 2005;6(6):383-92.
32. Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. *Journal of the American Academy of Dermatology*. 2012 Oct;67(4):651-7.
33. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. *The Australasian journal of dermatology*. 2004 Aug;45(3):155-9.
34. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. *Sleep medicine*. 2012 Mar;13(3):285-9.
35. Farley E, Menter A. Psoriasis: comorbidities and associations. *Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia*. 2011 Feb;146(1):9-15.
36. Slobodin G, Rosner I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic arthropathy: where now? *The Israel Medical Association journal : IMAJ*. 2009 Jul;11(7):430-4.
37. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *The British journal of dermatology*. 2010 Sep;163(3):586-92.
38. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications. *Journal of medicine and life*. 2014 Oct-Dec;7(4):468-71.
39. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. *Journal of the American Academy of Dermatology*. 2015 Apr 14.

- 1
2
3 40. Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, et al. Psoriasis in the US
4 Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic
5 Use. *J Invest Dermatol*. 2015 Dec;135(12):2955-63.
6
7
8 41. Wen ZH, Xuan ML, Yan YH, Li XY, Yao DN, Li G. Chinese medicine combined
9 with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris
10 (CMCBCOP): study protocol for a randomized controlled trial. *Trials*. 2014 Jul
11 22;15:294.
12
13 42. Parker S, Zhang AL, Zhang CS, Goodman G, Wen Z, Lu C. Oral granulated
14 Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris:
15 study protocol for a double-blind, randomized placebo controlled trial. *Trials*. 2014
16 Dec 19;15:495.
17
18 43. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K,
19 Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR,
20 Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D.
21 SPIRIT: Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern*
22 *Med* 2013, 2013:200–207.
23
24 44. Moher D, Schulz KF, Altman DG: CONSORT. The CONSORT statement:
25 revised recommendations for improving the quality of reports of parallel group
26 randomized trials. *BMC Med Res Methodol* 2001, 1:2.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure captions:

Figure 1. Flowchart of the study

Table captions:

Table 1. Schedule for treatment and outcome measure

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of the study.

297x420mm (300 x 300 DPI)

广东省中医院伦理委员会

Institutional Ethics Committee of Guangdong Provincial Hospital of Traditional
Chinese Medicine

知情同意书·知情告知页（研究简介）

Information Leaflet for Informed Consent

亲爱的患者

您的医生已经确诊您患有寻常型银屑病疾病。

我们将邀请您参加一项“YXBCM01 颗粒治疗寻常型银屑病的双盲双模拟随机对照试验”，本研究将“YXBCM01 颗粒”与院内制剂“银屑灵片”进行比较，以观察他们对于银屑病的疗效和安全性。治疗途径是中药颗粒剂冲溶口服以及片剂口服。

在您决定是否参加这项研究之前，请尽可能仔细阅读以下内容，它可以帮助您了解该项研究以及为何要进行这项研究，研究的程序和期限，参加研究后可能给您带来的益处、风险和不适。如果您愿意，您可以请您的医生给予解释，或者可以和您的家属、朋友一起讨论，帮助您做出决定。

研究介绍

一、研究背景和研究目的

银屑病是临床常见的皮肤病之一，目前西医治疗有一定效果，但存在不良反应大、复发率高和价格昂贵等缺点。中医学在治疗银屑病方面占有重要的地位，积累了丰富的治疗经验，可有效缓解症状、减少复发率、控制病情发展，且价格适宜，尚未发现不良反应，适合长期使用。

本项研究目的是采用双盲双模拟随机对照试验设计，观察优化方 YXBCM01 颗粒相对于银屑灵片剂的疗效，评价优化方是否非劣于片剂。

本研究将在 3 个研究中心进行，预计有 64 余名受试者自愿参加。

本项研究已经得到广东省中医院伦理委员会批准。广东省中医院伦理委员会已经审议此项研究是遵从赫尔辛基宣言原则，符合医疗道德的。

二、哪些人不宜参加研究

- ①皮损单独见于颜面、头皮、指甲、皱折、龟头、粘膜、掌跖部位的患者。
- ②银屑病急性进展、有红皮病倾向的患者。
- ③妊娠、哺乳期或 1 年内计划妊娠者。
- ④心理测量量表 SAS 标准分 > 50 分或 SDS 标准分 > 53 分，或合并其他精神疾病的患者。
- ⑤合并有循环系统、呼吸系统、消化系统、泌尿系统、内分泌系统和造血系统等严重原发性疾病、常规用药无法控制的患者，合并肿瘤的患者，有严重感染、水、电解质及酸碱平衡紊乱的患者。或临床检测指标属于以下几种情况之一的患者：谷丙转氨酶或谷草转氨酶增高 > 3 倍正常值上限；肌酐增高 > 1.5 倍正常值上限；血红蛋白增高 > 20g/L 正常值上限；血小板计数减少 < $75.0 \times 10^9/L$ ；白细胞计数减少 < $3.0 \times 10^9/L$ ；或其

他实验室检查异常研究者判断不适合参与此试验的患者。

⑥已知对本研究中所用药物过敏的患者。

⑦正在参加其它药物临床试验者或1个月内参加过其它临床试验者。

⑧2周内曾用激素、维甲酸类等外用药物治疗者；4周内曾接受系统治疗或紫外光治疗者；12周内曾使用生物制剂治疗者。

⑨需进行西医系统治疗的患者。

三、如果参加研究将需要做什么

1. 在您入选研究前，您将接受以下检查以确定您是否可以参加研究

医生将询问、记录您的病史，对您进行全面的体格检查。

您需要进行血常规、尿常规、肝功能、肾功能、心电图以及系统生物学指标（代谢组学、蛋白质组学、脂组学）检查。

2. 若您以上检查合格，将按以下步骤进行研究

研究开始将根据计算机提供的随机数字，决定您接受 YXBCM01 颗粒+银屑灵片模拟剂治疗或银屑灵片+ YXBCM01 颗粒模拟剂治疗。参加这项研究的患者分别有 50%的可能性被分入这两个不同的治疗组。您和您的医生都无法事先知道和选择任何一种治疗方法。治疗观察将持续 24 周。

治疗期 12 周：治疗期间，您将每 2 周到医院就诊，并如实向医生反映病情变化，医生将记录您的病情变化情况。同时，医生会给您做皮损严重程度评分、拍照、填表，治疗前后均有一次体检，包括血常规、尿常规、肝肾功能及心电图检查等安全性检查。（研究期间共采血 2 次、心电图检查 2 次）。

随访期间 12 周：这时候研究结束了。随访期间不用药物维持，您还应该每 4 周到医院就诊，医生将询问记录您病情的变化，给您做皮损严重程度评分、拍照、填表。如果您出现皮肤瘙痒等情况，医生会给予处理。（研究和随访期间，若您的病情出现加重，随时到医院复诊）

3. 需要您配合的其他事项

您需要按医生和您的约定的时间来医院就诊。您的随访非常重要，因为医生将判断您接受的治疗是否真正起作用。

您需要按医生指导用药，并请您在每次服药后及时、客观地在《患者日志》中记录。您在每次随访时都必须归还未用完的药物及其包装，并将正在服用的其他药物带来，包括您有其他合并疾病须继续服用的药物。

在研究期间您不能使用治疗银屑病的其他内服和外用药物。如您需要进行其他治疗，请事先与您的医生取得联系。

关于饮食、生活起居的规定：清淡饮食，避免感冒。

四、参加研究可能的受益

您和社会将可能从本项研究中受益。此种受益包括您的病情有可能获得改善，以及本项研究可能帮助开发出一种新治疗方法，以用于患有相似病情的其他病人。

您将在研究期间获得良好的医疗服务。

您将得到因参加临床试验的交通补贴。

五、参加研究可能的不良反应、风险和不适、不方便

所有治疗方法都有可能产生不良反应。尽管到目前为止没有发现该治疗方法有任何不良反应，如果在研究中您出现任何不适，或病情发生新的变化，或任何意外情况，不管是否与

治疗方法有关, 均应及时通知您的医生, 他/她将对作出判断和医疗处理。

医生将尽全力预防和治疗由于本研究可能带来的伤害。如果在临床试验中出现不良事件, 医学专家委员会将会鉴定其是否与试验有关。医院将对与试验相关的损害提供治疗的费用及法律法规规定相应的经济补偿。

您在研究期间需要按时到医院随访, 做一些理化检查, 这些都有可能给您造成麻烦或带来不便。

此外, 任何治疗都有可能出现无效情况, 以及因治疗无效或者因合并其他疾病等原因而导致病情继续发展。这是每个就医患者都将面临的治疗风险, 即使不参加本项临床研究, 治疗风险都将存在。在研究期间, 如果医生发现本项研究所采取的治疗措施无效, 将会终止研究, 改用其他可能有效的治疗措施。

六、有关费用

课题组将支付您参加本项研究期间所做的与研究有关的检查(血常规、尿常规、肝功能、肾功能及心电图检查)费用, 免挂号费, 并免费提供研究用药, 研究结束后您将得到因参加临床试验的交通补贴费 300 元。

如果发生与试验相关的损害, 课题组将支付您的医疗费用。如果严重不良反应住院医疗, 课题组将依照相关法律给予相应的补偿。

如果您同时合并其他疾病所需的治疗和检查, 将不在免费的范围之内。

七、个人信息保密的吗?

您的医疗记录(研究病历/CRF、化验单等)将完整地保存在医院, 医生会将化验检查结果记录在您的门诊病历上。研究者、申办者代表和伦理委员会将被允许查阅您的医疗记录。任何有关本项研究结果的公开报告将不会批露您的个人身份。我们将在法律允许的范围内, 尽一切努力保护您个人医疗资料的隐私。除本研究外, 有可能在今后的其他研究中会再次利用您的医疗记录和病理检查标本。

八、怎样获得更多的信息?

您可以在任何时间提出有关本项研究的任何问题。您的医生或研究者将给您留下他/她的电话号码以便能回答您的问题。

如果您对参加研究有任何抱怨, 请联系伦理委员会办公室。

如果在研究过程中有任何重要的新信息, 可能影响您继续参加研究的意愿时, 您的医生会及时通知您。

九、可以自愿选择参加研究和中途退出研究

是否参加研究完全取决于您的自愿。您可以拒绝参加此项研究, 或在研究过程中的任何时间退出本研究, 这都不会影响您和医生间的关系, 都不会影响对您的医疗有其他方面利益的损失。

您的医生或研究者出于对您的最大利益考虑, 可能会随时终止您参加本研究。

如果您不参加本研究, 或中途退出研究, 还有很多其他可替代的治疗方法, 如光疗法等。您不必为了治疗您的疾病而选择参加本研究。

如果您因为任何原因从研究中退出, 您可能被询问有关您使用试验方法的情况。如果医生认为需要, 您可能被要求进行实验室检查和体格检查。这对保护您的健康十分有利。

十、研究结束后标本会如何处理?

研究结束后,我们将储存本研究剩余的血液/皮肤标本,储存时间为10年。这些标本未来可能用于与皮肤病相关的其他科学研究,并按实际需求在不同的研究实验机构(包括国外机构)进行检测。

如果您同意把您的标本储存用于未来的研究,我们会给予标本代码/编号,同时对您的个人隐私信息进行严格保密,在和其他研究者共同利用这些标本进行研究时,保证不会泄露您的个人信息使其他人能识别这是您的标本。除了我们,其他研究者不会知道那个标本是属于您的。其他研究者必须通过标本所在机构的医学伦理委员会审查后才有权使用您的标本进行科学研究。

十一、现在该做什么?

在您做出参加研究的决定前,请尽可能向您的医生询问有关问题,直至您对本项研究完全理解。

是否参加本项研究由您自己决定。您可以和您的家人或者朋友讨论后再做出决定。

感谢您阅读以上材料。如果您决定参加本项研究,请告诉您的医生或研究助理,她会为您安排一切有关研究的事务。

请您保留这份资料。

知情同意书 · 同意签字页

Signature Leaflet for Informed Consent

临床研究项目名称: YXBCM01 颗粒治疗寻常型银屑病的双盲双模拟随机对照试验

有关课题资助单位的任务下达文件证明:

伦理审查批件号:

同意声明

我已经阅读了上述有关本研究的介绍, 而且有机会就此项研究与医生讨论并提出问题。我提出的所有问题都得到了满意的答复。

我知道参加本研究可能产生的风险和受益。我知晓参加研究是自愿的, 我确认已有充足时间对此进行考虑, 而且明白:

- 我随时可以向医生咨询更多的信息。
- 我可以随时退出本研究, 而且不会受到歧视或报复, 医疗待遇与权益不会受到影响。

我同样清楚, 如果我中途退出本研究, 特别是由于药物的原因使我退出研究时, 我将病情变化告诉医生, 完成相应的体格检查和理化检查, 这将对我本人和整个研究十分有利。

如果因患病我需要采取任何其他药物治疗, 我会在事先征求医生的意见, 或在事后如实告诉医生。

我同意药品监督管理部门、伦理委员会或申办者代表查阅我的研究资料。

我同意 或拒绝 除本研究以外的其他研究利用我的医疗记录和病理检查标本。

我将获得一份经过签名并注明日期的知情同意书副本。

最后, 我决定同意参加本项研究。

患者签名: _____ - - - - 年 - - 月 - - 日

志愿者的联系电话: _____ 手机号: _____

我确认已向患者解释了本试验的详细情况, 包括其权利以及可能的受益和风险, 并给其一份签署过的知情同意书副本。

医生签名: _____ 日期: _____ 年 _____ 月 _____ 日

医生的工作电话: _____ 手机号: _____

研究者办公室联系电话: 020-81887233-35934

Institutional Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

Informed Consent Form

This Informed Consent Form has two parts:

- Information Leaflet for Informed Consent (to share information about the study with you)
- Signature Leaflet for Informed Consent (for signatures if you agree that you may participate)

PART I: Information Leaflet for Informed Consent

Dear Sir/Madam,

We are doing research on psoriasis, which is very common in this country.

I am going to give you information and invite you to participate in a research PSORI-CM01 compared with Yinxieling for Psoriasis Vulgaris: a Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial. This research is to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granules compared with those of Yinxieling tablets for the treatment of patients with psoriasis. You do not have to decide today whether or not you agree that you may participate in the research. Before you decide, you can talk to anyone you feel comfortable with.

There may be some words that you do not understand. Please ask me to stop as we go through the information and I will take time to explain. If you have questions later, you can ask them of me, the study doctor or the staff.

Introduction

1. Background

Psoriasis is one of the most common diseases. The therapies that are currently being used is not as good as we would like it to be. Traditional Chinese medicine plays an important role in the treatment of psoriasis, has accumulated rich experience in the treatment, can effectively relieve symptoms and reduce the relapse rate, disease control, and the price is appropriate, has not found adverse reactions, suitable for long-term use. The purpose of this research to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granules compared with those of Yinxieling tablets for the treatment of patients with psoriasis.

2. Participant selection

1 The participants must meet all of the following criteria at the time of randomization to be
2 eligible for recruitment:

3
4 The participant must meet the criteria for the diagnosis of psoriasis vulgaris referred to in
5 the Clinical Guidelines of Psoriasis 2008 reported by the Chinese Medical Association.

6 Male and female patients must be between 18 and 65 years old.

7 PASI of more than 3 and less than 30, and a BSA of less than 30% are required.

8 The trial exclusion criteria include any of the following:

9 Psoriatic lesions can only be seen on the face, scalp, nails, anus, mucus and palmar-
10 plantar areas.

11 Acute progressive psoriasis, an erythroderma tendency, and psoriatic arthritis are present.

12 Participant who are pregnant, lactating, and those who plan to become pregnant within a
13 year will be excluded.

14 Those with an SAS more than 50 or an SDS more than 53, and those with other psychiatric
15 disorders will be excluded.

16 Those with a history of primary cardiovascular, respiratory, digestive, urinary,
17 endocrinologic and haematologic diseases that cannot be controlled with ordinary
18 treatments will be excluded. Those with malignant diseases, infections, electrolyte
19 imbalances, and acid-base disturbances will be excluded. Patients with the following
20 clinical test results will be excluded: an AST or ALT 3 times greater than the normal upper
21 limit, creatinine 1.5 times greater than the normal upper limit; haemoglobin elevated by 20
22 g/L above the normal upper limit; a platelet count less than $75.0 \times 10^9/L$; a white blood cell
23 count less than $3.0 \times 10^9/L$, and other abnormal laboratory test results, as assessed by the
24 investigators, which are not suitable for this clinical study.

25 Participants who are allergic to any medicine or ingredients used in this study will be
26 excluded.

27 Those participating other clinical trials and those who have participated in trials within 1
28 month will be excluded.

29 Participants who have used corticosteroids or retinoic acid acting on the skin over the
30 previous 2 weeks, those on systemic therapy or phototherapy (UVB and PUVA) with the
31 previous 4 weeks, and those on biological therapy over the previous 12 weeks will be
32 excluded.

3. Procedures and Protocol

33 Before you are selected for the study, you will be subject to the following examinations to
34 see if you can take part in the study.

35 The doctor will ask and record your medical history, and give you a thorough physical
36 examination.

37 You will need routine blood tests, urinalysis, liver function, renal function, ECG, and
38 systematic biological markers (metabolomics, proteomics, and lipid microscopy).

39 If you have passed the above inspection, you will follow the following steps:

1 Because we do not know if the PSORI-CM01 granule is better than Yinxieling tablets for
2 treating this disease, we need to make comparisons. You taking part in this research will be
3 put into groups which are selected by chance, as if by tossing a coin.

4 The healthcare workers will be looking after you and the other participants very carefully
5 during the study. If we are concerned about what the medicines or treatment is doing, we
6 will find out which treatment you are getting and make changes.

7 You may come to clinic during each of the visits and during the procedures. In the first visit,
8 a small amount of blood, equal to about a teaspoon will be taken from your arm. There
9 may be slight bruising but this will disappear in a few days.

10 In the next visit, you will be given either the PSORI-CM01 granule and placebo tablet or
11 the Yinxieling tablets and placebo granule that is used for psoriasis. Neither you nor we
12 will know, until later in the study, which treatments you were given. The drugs will be given
13 by a trained healthcare worker. After the treatment.

14 We will ask your physician to give us the details of your health and illness related
15 information. If you do not wish us to do that, please let us know. However, because your
16 health records are very important for the study, if we cannot look at the health records, we
17 will not be able to include you in the study.

18 At the end of the study, we will contact you by clinic to tell you which of the two treatments
19 you were given.

20 **4. Benefits**

21 If you participates in this research, you will have the following benefits: any treatment
22 about this research will be no charge to you. In addition, you will receive travel allowance
23 for clinical trials. There may not be any other benefit for you but your participation is
24 likely to help us find the answer to the research question. There may not be any benefit to
25 the society at this stage of the research, but future generations are likely to benefit.

26 **5. Side Effects**

27 These treatments can have some unwanted effects or some effects that we are not currently
28 aware of. However, we will follow you closely and keep track of these unwanted effects or
29 any problems. We will give you a telephone number to call if you notice anything out of the
30 ordinary, or if you have concerns or questions. You can also come to clinic at anytime and
31 ask to see us.

32 We may use some other medicines to decrease the symptoms of the side effects or reactions.
33 Or we may stop the use of one or more drugs. If this is necessary we will discuss it
34 together with you and you will always be consulted before we move to the next step.)

35 **6. Charge**

36 The charge for the examinations during the study (blood routine, urine routine, liver
37 function, kidney function and ECG) and relevant drugs will be free. After the end of the
38 study you will get 300 RMB for your lost time and travel expense. In case of side effects

1 associated with the study, we will pay your medical expenses. If you combine the treatment
2 and examination required for other diseases, you will not be free of charge.
3
4
5

6 **7. Confidentiality**

7 *The information that we collect from this research project will be kept confidential.*
8 *Information about you that will be collected from the research will be put away and no-one*
9 *but the researchers will be able to see it. Any information about you will have a code on it*
10 *instead of your name. Only the researchers will know what your code is and we will lock*
11 *that information up with a lock and key. It will not be shared with or given to anyone except*
12 *your clinician.*

13 *The knowledge that we get from this study will be shared with you before it is made widely*
14 *available to the public. Confidential information will not be shared. There will be small*
15 *meetings in the community and these will be announced. Afterwards, we will publish the*
16 *results in order that other interested people may learn from our research.*

17 **8. Getting for More Information**

18 *If you have any questions you may ask them now or later, even after the study has started.*
19 *If you wish to ask questions later, you may contact any of your clinician.*

20 *This proposal has been reviewed and approved by Institutional Ethics Committee of*
21 *Guangdong Provincial Hospital of Traditional Chinese Medicine, which is a committee*
22 *whose task it is to make sure that research participants are protected from harm. If you*
23 *wish to find about more about the Institutional Ethics Committee of Guangdong Provincial*
24 *Hospital of Traditional Chinese Medicine, contact Xiaoyan Li, 020-81887233-35934.*

25 **9. Right to Refuse or Withdraw**

26 *You do not have to agree to take part in this research if you do not wish to do so and*
27 *refusing to allow you to participate will not affect your treatment at this Centre in any way.*
28 *You will still have all the benefits that you would otherwise have at this Centre. You may*
29 *stop participating in the research at any time that you wish without losing any of your*
30 *rights as a patient here. Your treatment at this Centre will be affected in any way.*

31 **10. Biological Samples**

32 *The tissues/blood samples or any other human biological material will be stored for 10*
33 *years only for the research purpose. We will provide information about this and obtain*
34 *consent specifically for such storage and use in addition to consent for participation in the*
35 *study*

36 **11. Voluntary Participation**

37 *Before you make your decision to participate in the study, please ask your doctor questions*
38 *as much as possible until you fully understand the study.*
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Your decision to participate in this study is entirely voluntary. It is your choice whether to*
 2 *participate or not. You can discuss it with your family or friends before making a decision.*

3 *Thank you for reading this document. If you decide to participate in this study, please tell*
 4 *your doctor or research assistant, who will arrange all the research procedure for you.*
 5 *You will be given a copy of the full Informed Consent Form.*
 6
 7
 8
 9

10 **PART II: Signature Leaflet for Informed Consent**

11 **Trial: PSORI-CM01 compared with Yinxieling for Psoriasis Vulgaris: a** 12 **Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial.**

13 Certificate of Consent

14 I have read the foregoing information, or it has been read to me. I have had the opportunity
 15 to ask questions about it and any questions that I have asked have been answered to my
 16 satisfaction.

17 I also understand that I can *stop participating in the research at any time*, especially
 18 because side effect of the drugs. If I need to take any other medication, I'll ask the doctor
 19 for advice or tell the doctor exactly after the event.

20 I agree with the drug administration, the ethics committee, or the bid representative to
 21 review my research materials.

22 I agree with or refuse medical records and pathological examinations in this
 23 study for other use.

24 I will receive a signed copy of this informed consent.

25 I consent voluntarily to participate as a participant in this study.

26 **Signature of Participant** _____ **Date** _____

27 **Phone number of Participant** _____

28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39 I confirm that I have explained the details of the trial to the participant, including his/her
 40 rights and possible benefits and risks, and I have kept a copy of the signed informed
 41 consent.
 42
 43
 44

45 **Signature of Researcher /person taking the consent** _____

46 **Date** _____

47 **Phone number of Researcher /person taking the consent** _____

48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	7, Table.1
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	7-8
	7b	When applicable, explanation of any interim analyses and stopping guidelines	9
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	9
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	9
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and	9
10	diagram is strongly	were analysed for the primary outcome	
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons	
12	Recruitment	14a Dates defining the periods of recruitment and follow-up	12
13		14b Why the trial ended or was stopped	
14			
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was	
17		by original assigned groups	
18			
19	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	
20	estimation	precision (such as 95% confidence interval)	
21		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
22	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
23		pre-specified from exploratory	
24			
25	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
26			
27	Discussion		
28	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
29	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	
30	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
31			
32	Other information		
33	Registration	23 Registration number and name of trial registry	1
34	Protocol	24 Where the full trial protocol can be accessed, if available	
35	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	12
36			

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	15
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	1, 6,15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5
	6b	Explanation for choice of comparators	5
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6,7
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6,8
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	12
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, Table 1
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6-8, Figure 1

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
7				

Methods: Assignment of interventions (for controlled trials)

Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10,11
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10,11
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	10,11
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	10,11
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
29				
30				
31				

Methods: Data collection, management, and analysis

32				
33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11,12
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11.12
40				
41				
42				
43				
44				
45				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	12
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11,12
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	1, 6
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	6
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	6
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	NA
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	1
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	15
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary File
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	14
36				
37				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.